<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="pt" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Arq Bras Cardiol</journal-id><journal-id journal-id-type="publisher-id">abc</journal-id><journal-title-group><journal-title>Arquivos Brasileiros de Cardiologia</journal-title></journal-title-group><issn pub-type="ppub">0066-782X</issn><issn pub-type="epub">1678-4170</issn><publisher><publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38597552</article-id><article-id pub-id-type="pmc">PMC12094286</article-id>
<article-id pub-id-type="publisher-id">abc.20230138</article-id><article-id pub-id-type="doi">10.36660/abc.20230138</article-id><article-categories><subj-group subj-group-type="heading"><subject>Artigo Original</subject></subj-group></article-categories><title-group><article-title>Defici&#x000ea;ncia de Testosterona em Homens Hipertensos: Preval&#x000ea;ncia e Fatores Associados</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2678-4715</contrib-id><name><surname>Negretto</surname><given-names>Leandra Analia Freitas</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>An&#x000e1;lise estat&#x000ed;stica</role><role>Reda&#x000e7;&#x000e3;o do manuscrito</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do intelectual importante</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c1" ref-type="corresp"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0006-2145-3377</contrib-id><name><surname>Rassi</surname><given-names>Nelson</given-names></name><role>Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do intelectual importante</role><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Soares</surname><given-names>Leonardo Ribeiro</given-names></name><role>Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do intelectual importante</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Saraiva</surname><given-names>Amanda Bueno Carvalho</given-names></name><role>Obten&#x000e7;&#x000e3;o de dados</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4785-9651</contrib-id><name><surname>Teixeira</surname><given-names>Maria Em&#x000ed;lia Figueiredo</given-names></name><role>Obten&#x000e7;&#x000e3;o de dados</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Santos</surname><given-names>Luciana da Ressurrei&#x000e7;&#x000e3;o</given-names></name><role>Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do intelectual importante</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Souza</surname><given-names>Ana Luiza Lima</given-names></name><role>Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do intelectual importante</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5333-013X</contrib-id><name><surname>Jardim</surname><given-names>Paulo Cesar B. Veiga</given-names></name><role>Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do intelectual importante</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Barroso de Souza</surname><given-names>Weimar Kunz Sebba</given-names></name><role>Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do intelectual importante</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jardim</surname><given-names>Thiago de Souza Veiga</given-names></name><role>Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do intelectual importante</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><aff id="aff1">
<label>1</label>
<institution content-type="orgname">Universidade Federal de Goi&#x000e1;s &#x02013; Liga de Hipertens&#x000e3;o Arterial</institution>
<addr-line>
<named-content content-type="city">Goi&#x000e2;nia</named-content>
<named-content content-type="state">GO</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Universidade Federal de Goi&#x000e1;s &#x02013; Liga de Hipertens&#x000e3;o Arterial, Goi&#x000e2;nia, GO &#x02013; Brasil</institution>
</aff><aff id="aff2">
<label>2</label>
<institution content-type="orgname">Hospital Geral de Goi&#x000e2;nia &#x02013; Dr. Alberto Rassi</institution>
<addr-line>
<named-content content-type="city">Goi&#x000e2;nia</named-content>
<named-content content-type="state">GO</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Hospital Geral de Goi&#x000e2;nia &#x02013; Dr. Alberto Rassi, Goi&#x000e2;nia, GO &#x02013; Brasil</institution>
</aff></contrib-group><author-notes><corresp id="c1">
<bold>Correspond&#x000ea;ncia: Leandra Analia Freitas Negretto</bold>
&#x02022; Universidade Federal de Goi&#x000e1;s &#x02013; Liga de Hipertens&#x000e3;o Arterial &#x02013; 5 avenida, 7692. CEP
<postal-code>74605-220</postal-code>
, Setor Leste Universit&#x000e1;rio, Goi&#x000e2;nia, GO &#x02013; Brasil E-mail:
<email>lenegretto@gmail.com</email>
</corresp><fn fn-type="COI-statement"><p>
<bold>Potencial conflito de interesse</bold>
</p><p>N&#x000e3;o h&#x000e1; conflito com o presente artigo.</p></fn></author-notes><pub-date pub-type="epub"><day>21</day><month>3</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2024</year></pub-date><volume>121</volume><issue>3</issue><elocation-id>e20230138</elocation-id><history><date date-type="received"><day>18</day><month>7</month><year>2023</year></date><date date-type="rev-recd"><day>27</day><month>10</month><year>2023</year></date><date date-type="accepted"><day>14</day><month>11</month><year>2023</year></date></history><permissions><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License</license-p></license></permissions><abstract><title>Resumo</title><sec><title>Fundamento:</title><p>A defici&#x000ea;ncia de testosterona (DT) &#x000e9; uma condi&#x000e7;&#x000e3;o prevalente em nosso meio e ainda muito negligenciada. A hipertens&#x000e3;o arterial (HA) &#x000e9; um de seus poss&#x000ed;veis fatores associados.</p></sec><sec><title>Objetivos:</title><p>Determinar a preval&#x000ea;ncia de DT em uma popula&#x000e7;&#x000e3;o masculina hipertensa e os fatores associados &#x000e0; sua ocorr&#x000ea;ncia, como idade, tempo de diagn&#x000f3;stico de HA, n&#x000fa;mero de classes de anti-hipertensivos, &#x000ed;ndice de massa corporal (IMC), diabetes, dislipidemia, doen&#x000e7;a renal cr&#x000f4;nica (DRC), sintomas positivos de DT (question&#x000e1;rio ADAM positivo) e uso de espironolactona.</p></sec><sec><title>M&#x000e9;todos:</title><p>Estudo transversal com aplica&#x000e7;&#x000e3;o do question&#x000e1;rio ADAM, e avalia&#x000e7;&#x000e3;o de dados bioqu&#x000ed;micos, cl&#x000ed;nicos e antropom&#x000e9;tricos. Os pacientes foram estratificados em grupos de DT e testosterona normal. As vari&#x000e1;veis categ&#x000f3;ricas foram comparadas pelo teste do qui-quadrado e as vari&#x000e1;veis cont&#x000ed;nuas pelo teste de Mann-Witney; as vari&#x000e1;veis com signific&#x000e2;ncia (p&#x0003c;0,05) foram submetidas &#x000e0; regress&#x000e3;o linear multivariada.</p></sec><sec><title>Resultados:</title><p>A preval&#x000ea;ncia de DT foi de 26,8%. Houve associa&#x000e7;&#x000e3;o entre DT e IMC (p=0,0007), mas n&#x000e3;o houve com idade (p=0,0520), tempo de diagn&#x000f3;stico de HA (p=0,1418), n&#x000fa;mero de classes de anti-hipertensivos (p=0,0732), diabetes (p=0,1112); dislipidemia (p=0,3888); presen&#x000e7;a de DRC (p=0,3321); uso de espironolactona (p=0,3546) e question&#x000e1;rio ADAM positivo (p=0,2483).</p></sec><sec><title>Conclus&#x000f5;es:</title><p>A preval&#x000ea;ncia de DT foi alta e houve associa&#x000e7;&#x000e3;o positiva com IMC. A testosterona total (TT) declinou 8,44 ng/dL com o aumento de 1 kg/m<sup>2</sup> no IMC e caiu 3,79 ng/dL com o avan&#x000e7;o em um ano na idade.</p></sec></abstract><kwd-group><title>Palavras-chave:</title><kwd>Testosterona</kwd><kwd>Hipertens&#x000e3;o</kwd><kwd>Obesidade</kwd><kwd>Hipogonadismo</kwd></kwd-group><counts><fig-count count="6"/><table-count count="8"/><equation-count count="0"/><ref-count count="32"/></counts></article-meta></front><body><fig position="float" id="f3"><graphic xlink:href="0066-782X-abc-121-03-e20230138-gf03" position="float"/></fig><sec sec-type="intro"><title>Introdu&#x000e7;&#x000e3;o</title><p>A defici&#x000ea;ncia de testosterona (DT) &#x000e9; resultante da falha testicular em produzir n&#x000ed;veis fisiol&#x000f3;gicos de testosterona (T) devido &#x000e0; ruptura de um ou mais elementos do eixo hipot&#x000e1;lamo-hip&#x000f3;fise-test&#x000ed;culo (HHT). Quando a DT &#x000e9; confirmada e est&#x000e1; associada a sinais cl&#x000ed;nicos de defici&#x000ea;ncia androg&#x000ea;nica, configura-se o hipogonadismo masculino.<sup>
<xref rid="B1" ref-type="bibr">1</xref>
</sup> A preval&#x000ea;ncia de hipogonadismo, na popula&#x000e7;&#x000e3;o geral masculina, varia com a idade, sendo de seis a 12,3% entre 40 e 69 anos, respectivamente.<sup>
<xref rid="B2" ref-type="bibr">2</xref>
</sup></p><p>A DT pode causar diversos sinais e sintomas, que dependem da idade de apresenta&#x000e7;&#x000e3;o e de sua gravidade,<sup>
<xref rid="B3" ref-type="bibr">3</xref>
</sup> como: diminui&#x000e7;&#x000e3;o da libido, disfun&#x000e7;&#x000e3;o er&#x000e9;til, diminui&#x000e7;&#x000e3;o do volume de ejacula&#x000e7;&#x000e3;o, perda de pelos corporais e faciais, fraqueza, diminui&#x000e7;&#x000e3;o da densidade &#x000f3;ssea, diminui&#x000e7;&#x000e3;o da massa magra, aumento da gordura corporal, fadiga e anemia.<sup>
<xref rid="B3" ref-type="bibr">3</xref>
,
<xref rid="B4" ref-type="bibr">4</xref>
</sup> Al&#x000e9;m disso, a sobrevida de homens com baixos n&#x000ed;veis de T &#x000e9; inferior &#x000e0; de homens com valores normais de T (eugonadismo), sendo a mortalidade por todas as causas de 34,9%
<italic toggle="yes">vs</italic>
. 20,1%, respectivamente.<sup>
<xref rid="B5" ref-type="bibr">5</xref>
</sup></p><p>A hipertens&#x000e3;o arterial (HA) foi associada &#x000e0; DT em alguns estudos, como no estudo
<italic toggle="yes">"Hypogonadism in males"</italic>
(HIM),<sup>
<xref rid="B6" ref-type="bibr">6</xref>
</sup> no qual foi observado que uma propor&#x000e7;&#x000e3;o mais alta de pacientes com DT era hipertensa em compara&#x000e7;ao a indiv&#x000ed;duos com n&#x000ed;veis normais do horm&#x000f4;nio. Segundo Svartberg et al.,7 indiv&#x000ed;duos hipertensos ter&#x000e3;o valores totais de T menores que os n&#x000e3;o hipertensos, independente da idade. J&#x000e1; Smith et al.,8 mostraram que a priva&#x000e7;&#x000e3;o androg&#x000ea;nica em homens em tratamento contra c&#x000e2;ncer de pr&#x000f3;stata poderia induzir HA.</p><p>A rela&#x000e7;&#x000e3;o entre HA e DT ainda possui diversas lacunas, incluindo aspectos epidemiol&#x000f3;gicos, diagn&#x000f3;sticos e terap&#x000ea;uticos. Nesse contexto, o objetivo do presente estudo foi determinar a preval&#x000ea;ncia de DT em uma popula&#x000e7;&#x000e3;o brasileira de homens hipertensos acompanhados em servi&#x000e7;o de refer&#x000ea;ncia no tratamento da HA. Ainda, o estudo avaliou, nessa popula&#x000e7;&#x000e3;o, fatores associados &#x000e0; sua ocorr&#x000ea;ncia &#x02013; idade, tempo de diagn&#x000f3;stico de HA, n&#x000fa;mero de classes de anti-hipertensivos utilizados, &#x000ed;ndice de massa corporal (IMC),<sup>
<xref rid="B9" ref-type="bibr">9</xref>
</sup> presen&#x000e7;a de diabetes mellitus (DM),<sup>
<xref rid="B10" ref-type="bibr">10</xref>
</sup> dislipidemia (DLP),<sup>
<xref rid="B11" ref-type="bibr">11</xref>
</sup> doen&#x000e7;a renal cr&#x000f4;nica (DRC),<sup>
<xref rid="B12" ref-type="bibr">12</xref>
</sup> sintomas de defici&#x000ea;ncia androg&#x000ea;nica (segundo o question&#x000e1;rio ADAM,
<italic toggle="yes">Androgen Deficiency, in the Aging Male"</italic>
<sup>
<xref rid="B13" ref-type="bibr">13</xref>
</sup>) e uso de espironolactona.</p></sec><sec sec-type="methods"><title>M&#x000e9;todos</title><sec><title>Desenho do estudo</title><p>Estudo transversal realizado em servi&#x000e7;o de refer&#x000ea;ncia no tratamento da HA na regi&#x000e3;o central do Brasil. Os dados foram coletados pela equipe assistente durante consultas ambulatoriais.</p></sec><sec><title>Participantes</title><p>Para serem inclu&#x000ed;dos, os pacientes deveriam ter idade entre 18 e 85 anos, ser do sexo masculino, e comparecer &#x000e0;s consultas ambulatoriais ao menos uma vez ao ano. Foram exclu&#x000ed;dos pacientes que n&#x000e3;o realizaram os exames solicitados, transsexuais, e pacientes que apresentavam d&#x000e9;ficits cognitivos que os incapacitassem a responder ao question&#x000e1;rio ADAM.<sup>
<xref rid="B13" ref-type="bibr">13</xref>
</sup></p><p>O c&#x000e1;lculo amostral foi utilizando o G*Power 3,1, adotando preval&#x000ea;ncia esperada de 12%,<sup>
<xref rid="B2" ref-type="bibr">2</xref>
</sup> intervalo de confian&#x000e7;a (IC) de 95%, n&#x000ed;vel de signific&#x000e2;ncia de 0,05 e 80% de poder do teste, resultando no tamanho m&#x000ed;nimo de 148 indiv&#x000ed;duos.</p></sec><sec><title>Procedimentos de coleta de dados</title><p>Nesta pesquisa, foram consideradas as vari&#x000e1;veis: idade, tempo de diagn&#x000f3;stico de HA, n&#x000fa;mero de classes de anti-hipertensivos usados, uso de espironolactona, IMC,<sup>
<xref rid="B9" ref-type="bibr">9</xref>
</sup> presen&#x000e7;a DM,<sup>
<xref rid="B10" ref-type="bibr">10</xref>
</sup> DLP,<sup>
<xref rid="B11" ref-type="bibr">11</xref>
</sup> DRC,<sup>
<xref rid="B12" ref-type="bibr">12</xref>
</sup> al&#x000e9;m de sintomas positivos de defici&#x000ea;ncia androg&#x000ea;nica (question&#x000e1;rio ADAM<sup>
<xref rid="B13" ref-type="bibr">13</xref>
</sup>).</p><p>Durante consultas ambulatoriais, ap&#x000f3;s a assinatura do termo de consentimento livre e esclarecido (TCLE), foram aferidos peso e altura, pesquisadas as vari&#x000e1;veis mencionadas e solicitados exames incluindo dosagem de T total (TT). Para definir DT o ponto de corte de TT foi menor que 300 ng/dL (12nmol/L), conforme as recomenda&#x000e7;&#x000f5;es da
<italic toggle="yes">Endocrine Society</italic>
<sup>
<xref rid="B1" ref-type="bibr">1</xref>
</sup> e da
<italic toggle="yes">American Urological Association</italic>
.<sup>
<xref rid="B14" ref-type="bibr">14</xref>
</sup> As amostras de sangue foram coletadas em jejum, pela manh&#x000e3;, e os exames foram realizados por laborat&#x000f3;rios rand&#x000f4;micos que utilizam a metodologia dos imunoensaios.15</p><p>O question&#x000e1;rio ADAM, da Universidade de Saint Louis, consiste em 10 perguntas sobre sintomas de defici&#x000ea;ncia androg&#x000ea;nica do tipo "sim ou n&#x000e3;o".<sup>
<xref rid="B13" ref-type="bibr">13</xref>
</sup> Esse question&#x000e1;rio apresenta sensibilidade de 88% e especificidade de 60%,<sup>
<xref rid="B16" ref-type="bibr">16</xref>
</sup> sendo o seu emprego recomendando como instrumento de triagem de hipogonadismo.<sup>
<xref rid="B17" ref-type="bibr">17</xref>
</sup></p></sec><sec><title>An&#x000e1;lise estat&#x000ed;stica</title><p>Foram avaliados 239 participantes e estratificados em dois grupos segundo o
<italic toggle="yes">status</italic>
de TT em: (1) indiv&#x000ed;duos com DT (
<italic toggle="yes">n</italic>
=64; 26,8%) e (2) eugon&#x000e1;dicos (
<italic toggle="yes">n</italic>
=175; 73,2%). Na estat&#x000ed;stica descritiva, foram calculadas, para as vari&#x000e1;veis categ&#x000f3;ricas: as frequ&#x000ea;ncias absolutas (
<italic toggle="yes">n</italic>
) e relativas percentuais [
<italic toggle="yes">f(%)</italic>
]; e para as vari&#x000e1;veis cont&#x000ed;nuas: mediana e intervalo interquartil (IIQ). As vari&#x000e1;veis categ&#x000f3;ricas foram:
<italic toggle="yes">status</italic>
de TT; idade; tempo de HA; n&#x000fa;mero de classes de anti-hipertensivos; IMC; DM; DLP; DRC; uso de espironolactona e question&#x000e1;rio ADAM. As vari&#x000e1;veis quantitativas cont&#x000ed;nuas foram: idade; tempo de HA; n&#x000fa;mero de classes de anti-hipertensivos; IMC; e n&#x000ed;vel de TT (em ng/dL).</p><p>Para a estat&#x000ed;stica inferencial, as vari&#x000e1;veis categ&#x000f3;ricas, estratificadas pelo
<italic toggle="yes">status</italic>
de TT, foram comparadas pelos testes: qui-quadrado, exato de Fisher ou G. Para a vari&#x000e1;vel com signific&#x000e2;ncia estat&#x000ed;stica, foram calculados Odds Ratio (OR) e IC de 95% para avaliar as chances de apresentar DT entre as categorias.</p><p>Para as vari&#x000e1;veis cont&#x000ed;nuas, foram calculadas a normalidade dos dados com o teste de Kolmogorov-Smirnov e a homogeneidade de vari&#x000e2;ncia, pelo teste de Levene. Todas as vari&#x000e1;veis cont&#x000ed;nuas apresentaram distribui&#x000e7;&#x000e3;o n&#x000e3;o param&#x000e9;trica sem homogeneidade (p&#x0003c;0,05). Desta forma, foi aplicado o teste de Mann-Whitney para amostras independentes. Posteriormente, para as vari&#x000e1;veis com p&#x0003c;0,20, foi aplicado teste de regress&#x000e3;o linear multivariada. Finalmente, foi aplicado o teste de correla&#x000e7;&#x000e3;o de Spearman.<sup>
<xref rid="B18" ref-type="bibr">18</xref>
</sup></p></sec></sec><sec sec-type="results"><title>Resultados</title><p>Foram recrutados 276 homens hipertensos; 37 participantes foram exclu&#x000ed;dos &#x02013; 18 apresentavam idade superior a 85 anos, 11 se recusaram a participar do estudo, tr&#x000ea;s apresentavam d&#x000e9;ficit cognitivo, dois tinham esquizofrenia, dois faleceram antes da coleta de sangue para medida do TT e um era transexual. Entre os 239 participantes inclu&#x000ed;dos, 175 (73,2%) apresentaram n&#x000ed;veis normais de TT (eugonadismo) e 64 apresentaram n&#x000ed;veis baixos de TT, determinando a preval&#x000ea;ncia de DT em 26,8%. Os resultados est&#x000e3;o sintetizados na Figura Central.</p><p>A
<xref rid="t1" ref-type="table">Tabela 1</xref>
apresenta as vari&#x000e1;veis
<italic toggle="yes">status</italic>
de TT, ou seja, DT ou eugon&#x000e1;dico, idade, tempo de diagn&#x000f3;stico de HA, n&#x000fa;mero de classes de anti-hipertensivos, IMC,<sup>
<xref rid="B9" ref-type="bibr">9</xref>
</sup> diagn&#x000f3;stico de DM,<sup>
<xref rid="B10" ref-type="bibr">10</xref>
</sup> DLP,<sup>
<xref rid="B11" ref-type="bibr">11</xref>
</sup> e DRC,<sup>
<xref rid="B12" ref-type="bibr">12</xref>
</sup> uso de espironolactona e question&#x000e1;rio ADAM.<sup>
<xref rid="B13" ref-type="bibr">13</xref>
</sup> Esses dados est&#x000e3;o apresentados como frequ&#x000ea;ncia absoluta
<italic toggle="yes">(n)</italic>
e relativa percentual [
<italic toggle="yes">f(%)</italic>
].</p><table-wrap position="float" id="t1"><label>Tabela 1</label><caption><title>Estat&#x000ed;stica descritiva das vari&#x000e1;veis categ&#x000f3;ricas, expressas como frequ&#x000ea;ncia absoluta (
<italic toggle="yes">n</italic>
) e relativa percentual [
<italic toggle="yes">f(%)</italic>
], dos 239 participantes; Goi&#x000e2;nia, Brasil, 2023</title></caption><table frame="hsides" rules="groups"><colgroup width="32%" span="1"><col width="1%" span="1"/><col width="1%" span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000"><tr style="background-color:#76B4CF"><th valign="middle" align="left" colspan="3" rowspan="1">Vari&#x000e1;veis (N=239)</th><th valign="middle" align="center" rowspan="1" colspan="1">n</th><th valign="middle" align="center" rowspan="1" colspan="1">f(%)</th></tr></thead><tbody style="border-bottom: thin solid; border-color: #000000"><tr><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>
<italic toggle="yes">Status</italic>
de Testosterona</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Defici&#x000ea;ncia de Testosterona</td><td valign="middle" align="center" rowspan="1" colspan="1">64</td><td valign="middle" align="center" rowspan="1" colspan="1">26,8</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Eugon&#x000e1;dico</td><td valign="middle" align="center" rowspan="1" colspan="1">175</td><td valign="middle" align="center" rowspan="1" colspan="1">73,2</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Idade (anos)</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">At&#x000e9; 60 anos</td><td valign="middle" align="center" rowspan="1" colspan="1">91</td><td valign="middle" align="center" rowspan="1" colspan="1">38,1</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">60 anos ou mais</td><td valign="middle" align="center" rowspan="1" colspan="1">148</td><td valign="middle" align="center" rowspan="1" colspan="1">61,9</td></tr><tr><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Tempo de HA (anos)</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">At&#x000e9; 15 anos</td><td valign="middle" align="center" rowspan="1" colspan="1">126</td><td valign="middle" align="center" rowspan="1" colspan="1">52,7</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Acima de 15 anos</td><td valign="middle" align="center" rowspan="1" colspan="1">97</td><td valign="middle" align="center" rowspan="1" colspan="1">40,6</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Sem Informa&#x000e7;&#x000e3;o</td><td valign="middle" align="center" rowspan="1" colspan="1">16</td><td valign="middle" align="center" rowspan="1" colspan="1">6,7</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>N&#x000fa;mero de classes de anti-hipertensivos</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Nenhum</td><td valign="middle" align="center" rowspan="1" colspan="1">8</td><td valign="middle" align="center" rowspan="1" colspan="1">3,3</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">At&#x000e9; 3</td><td valign="middle" align="center" rowspan="1" colspan="1">184</td><td valign="middle" align="center" rowspan="1" colspan="1">77,0</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Acima de 3</td><td valign="middle" align="center" rowspan="1" colspan="1">47</td><td valign="middle" align="center" rowspan="1" colspan="1">19,7</td></tr><tr><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>IMC (kg/m<sup>2</sup>)</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Normal (18,6 at&#x000e9; 24,9)</td><td valign="middle" align="center" rowspan="1" colspan="1">51</td><td valign="middle" align="center" rowspan="1" colspan="1">21,3</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Sobrepeso (25,0 at&#x000e9; 29,9)</td><td valign="middle" align="center" rowspan="1" colspan="1">100</td><td valign="middle" align="center" rowspan="1" colspan="1">41,8</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Obesidade (&#x02265;30,0)</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1">Grau I (30,0 at&#x000e9; 34,9)</td><td valign="middle" align="center" rowspan="1" colspan="1">58</td><td valign="middle" align="center" rowspan="1" colspan="1">24,3</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1">Grau II (35,0 at&#x000e9; 39,0)</td><td valign="middle" align="center" rowspan="1" colspan="1">20</td><td valign="middle" align="center" rowspan="1" colspan="1">8,4</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1">Grau III (&#x02265;40,0)</td><td valign="middle" align="center" rowspan="1" colspan="1">8</td><td valign="middle" align="center" rowspan="1" colspan="1">3,3</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Sem Informa&#x000e7;&#x000e3;o</td><td valign="middle" align="center" rowspan="1" colspan="1">2</td><td valign="middle" align="center" rowspan="1" colspan="1">0,8</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Diabetes</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Sim</td><td valign="middle" align="center" rowspan="1" colspan="1">78</td><td valign="middle" align="center" rowspan="1" colspan="1">32,6</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">N&#x000e3;o</td><td valign="middle" align="center" rowspan="1" colspan="1">161</td><td valign="middle" align="center" rowspan="1" colspan="1">67,4</td></tr><tr><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Dislipidemia</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Sim</td><td valign="middle" align="center" rowspan="1" colspan="1">172</td><td valign="middle" align="center" rowspan="1" colspan="1">72,0</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">N&#x000e3;o</td><td valign="middle" align="center" rowspan="1" colspan="1">67</td><td valign="middle" align="center" rowspan="1" colspan="1">28,0</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>DRC</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Sim</td><td valign="middle" align="center" rowspan="1" colspan="1">78</td><td valign="middle" align="center" rowspan="1" colspan="1">32,6</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">N&#x000e3;o</td><td valign="middle" align="center" rowspan="1" colspan="1">161</td><td valign="middle" align="center" rowspan="1" colspan="1">67,4</td></tr><tr><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Espironolactona</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Sim</td><td valign="middle" align="center" rowspan="1" colspan="1">23</td><td valign="middle" align="center" rowspan="1" colspan="1">9,6</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">N&#x000e3;o</td><td valign="middle" align="center" rowspan="1" colspan="1">216</td><td valign="middle" align="center" rowspan="1" colspan="1">90,4</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Question&#x000e1;rio ADAM</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Negativo</td><td valign="middle" align="center" rowspan="1" colspan="1">24</td><td valign="middle" align="center" rowspan="1" colspan="1">10,0</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Positivo</td><td valign="middle" align="center" rowspan="1" colspan="1">184</td><td valign="middle" align="center" rowspan="1" colspan="1">77,0</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Sem Informa&#x000e7;&#x000e3;o</td><td valign="middle" align="center" rowspan="1" colspan="1">31</td><td valign="middle" align="center" rowspan="1" colspan="1">13,0</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>N: n&#x000fa;mero total de indiv&#x000ed;duos no grupo amostral; n: frequ&#x000ea;ncia absoluta; f(%): frequ&#x000ea;ncia relativa percentual; HA: hipertens&#x000e3;o arterial; IMC: &#x000ed;ndice de massa corporal; DRC: doen&#x000e7;a renal cr&#x000f4;nica; Question&#x000e1;rio ADAM (do ingl&#x000ea;s,
<italic toggle="yes">Androgen Deficiency, in the Aging Male</italic>
).</p></fn></table-wrap-foot></table-wrap><p>A
<xref rid="t2" ref-type="table">Tabela 2</xref>
compara as vari&#x000e1;veis e suas categorias entre os grupos DT e eugon&#x000e1;dicos. Foi observada diferen&#x000e7;a estatisticamente significativa nas categorias de IMC (p=0,0007) entre os grupos, sendo observado maior n&#x000fa;mero de indiv&#x000ed;duos com obesidade nos pacientes com DT.</p><table-wrap position="float" id="t2"><label>Tabela 2</label><caption><title>Estat&#x000ed;stica inferencial das vari&#x000e1;veis categ&#x000f3;ricas, dos 239 participantes, estratificados pelo
<italic toggle="yes">status</italic>
de testosterona. Goi&#x000e2;nia, Goi&#x000e1;s, Brasil, 2023</title></caption><table frame="hsides" rules="groups"><colgroup width="16%" span="1"><col width="1%" span="1"/><col width="1%" span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000"><tr style="background-color:#76B4CF"><th valign="middle" align="left" colspan="3" rowspan="2">Vari&#x000e1;veis (N=239)</th><th valign="middle" align="center" colspan="2" style="border-bottom: thin solid; border-color: #000000" rowspan="1">D&#x000e9;ficit Testosterona (n=64; 26,8%)</th><th valign="middle" align="center" colspan="2" style="border-bottom: thin solid; border-color: #000000" rowspan="1">Eugon&#x000e1;dico (n=175; 73,2%)</th><th valign="middle" align="center" rowspan="2" colspan="1">p-valor
<xref rid="TFN3" ref-type="table-fn">*</xref></th></tr><tr style="background-color:#76B4CF"><th valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</th><th valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">f(%)</italic>
</th><th valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</th><th valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">f(%)</italic>
</th></tr></thead><tbody style="border-bottom: thin solid; border-color: #000000"><tr><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Idade (anos)</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">At&#x000e9; 60 anos</td><td valign="middle" align="center" rowspan="1" colspan="1">18</td><td valign="middle" align="center" rowspan="1" colspan="1">28,1</td><td valign="middle" align="center" rowspan="1" colspan="1">73</td><td valign="middle" align="center" rowspan="1" colspan="1">41,7</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">60 anos ou mais</td><td valign="middle" align="center" rowspan="1" colspan="1">46</td><td valign="middle" align="center" rowspan="1" colspan="1">71,9</td><td valign="middle" align="center" rowspan="1" colspan="1">102</td><td valign="middle" align="center" rowspan="1" colspan="1">58,3</td><td valign="middle" align="center" rowspan="1" colspan="1">0,0520</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Tempo de HA (anos)</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">At&#x000e9; 15 anos</td><td valign="middle" align="center" rowspan="1" colspan="1">28</td><td valign="middle" align="center" rowspan="1" colspan="1">43,8</td><td valign="middle" align="center" rowspan="1" colspan="1">98</td><td valign="middle" align="center" rowspan="1" colspan="1">56,0</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Acima de 15 anos</td><td valign="middle" align="center" rowspan="1" colspan="1">30</td><td valign="middle" align="center" rowspan="1" colspan="1">46,9</td><td valign="middle" align="center" rowspan="1" colspan="1">67</td><td valign="middle" align="center" rowspan="1" colspan="1">38,3</td><td valign="middle" align="center" rowspan="1" colspan="1">0,1418</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Sem Informa&#x000e7;&#x000e3;o</td><td valign="middle" align="center" rowspan="1" colspan="1">6</td><td valign="middle" align="center" rowspan="1" colspan="1">9,4</td><td valign="middle" align="center" rowspan="1" colspan="1">10</td><td valign="middle" align="center" rowspan="1" colspan="1">5,7</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>N&#x000fa;mero de classes de anti-hipertensivos</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Nenhum</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td><td valign="middle" align="center" rowspan="1" colspan="1">0,0</td><td valign="middle" align="center" rowspan="1" colspan="1">8</td><td valign="middle" align="center" rowspan="1" colspan="1">4,6</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">At&#x000e9; 3</td><td valign="middle" align="center" rowspan="1" colspan="1">52</td><td valign="middle" align="center" rowspan="1" colspan="1">81,3</td><td valign="middle" align="center" rowspan="1" colspan="1">132</td><td valign="middle" align="center" rowspan="1" colspan="1">75,4</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Acima de 3</td><td valign="middle" align="center" rowspan="1" colspan="1">12</td><td valign="middle" align="center" rowspan="1" colspan="1">18,8</td><td valign="middle" align="center" rowspan="1" colspan="1">35</td><td valign="middle" align="center" rowspan="1" colspan="1">20,0</td><td valign="middle" align="center" rowspan="1" colspan="1">0,0732</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>IMC (kg/m<sup>2</sup>)</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Normal (18,6 at&#x000e9; 24,9)</td><td valign="middle" align="center" rowspan="1" colspan="1">5</td><td valign="middle" align="center" rowspan="1" colspan="1">7,8</td><td valign="middle" align="center" rowspan="1" colspan="1">46</td><td valign="middle" align="center" rowspan="1" colspan="1">26,3</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Sobrepeso(25,0 at&#x000e9; 29,9)</td><td valign="middle" align="center" rowspan="1" colspan="1">23</td><td valign="middle" align="center" rowspan="1" colspan="1">35,9</td><td valign="middle" align="center" rowspan="1" colspan="1">77</td><td valign="middle" align="center" rowspan="1" colspan="1">44,0</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Obesidade(&#x02265;30,0)</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1">Grau I (30,0 at&#x000e9; 34,9)</td><td valign="middle" align="center" rowspan="1" colspan="1">24</td><td valign="middle" align="center" rowspan="1" colspan="1">37,5</td><td valign="middle" align="center" rowspan="1" colspan="1">34</td><td valign="middle" align="center" rowspan="1" colspan="1">19,4</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1">Grau II (35,0 at&#x000e9; 39,0)</td><td valign="middle" align="center" rowspan="1" colspan="1">9</td><td valign="middle" align="center" rowspan="1" colspan="1">14,1</td><td valign="middle" align="center" rowspan="1" colspan="1">11</td><td valign="middle" align="center" rowspan="1" colspan="1">6,3</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1">Grau III (&#x02265;40,0)</td><td valign="middle" align="center" rowspan="1" colspan="1">3</td><td valign="middle" align="center" rowspan="1" colspan="1">4,7</td><td valign="middle" align="center" rowspan="1" colspan="1">5</td><td valign="middle" align="center" rowspan="1" colspan="1">2,9</td><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>0,0007</bold>
</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Sem Informa&#x000e7;&#x000e3;o</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td><td valign="middle" align="center" rowspan="1" colspan="1">0,0</td><td valign="middle" align="center" rowspan="1" colspan="1">2</td><td valign="middle" align="center" rowspan="1" colspan="1">1,1</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Diabetes</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Sim</td><td valign="middle" align="center" rowspan="1" colspan="1">26</td><td valign="middle" align="center" rowspan="1" colspan="1">40,6</td><td valign="middle" align="center" rowspan="1" colspan="1">52</td><td valign="middle" align="center" rowspan="1" colspan="1">29,7</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">N&#x000e3;o</td><td valign="middle" align="center" rowspan="1" colspan="1">38</td><td valign="middle" align="center" rowspan="1" colspan="1">59,4</td><td valign="middle" align="center" rowspan="1" colspan="1">123</td><td valign="middle" align="center" rowspan="1" colspan="1">70,3</td><td valign="middle" align="center" rowspan="1" colspan="1">0,1112</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Dislipidemia</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Sim</td><td valign="middle" align="center" rowspan="1" colspan="1">49</td><td valign="middle" align="center" rowspan="1" colspan="1">76,6</td><td valign="middle" align="center" rowspan="1" colspan="1">123</td><td valign="middle" align="center" rowspan="1" colspan="1">70,3</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">N&#x000e3;o</td><td valign="middle" align="center" rowspan="1" colspan="1">15</td><td valign="middle" align="center" rowspan="1" colspan="1">23,4</td><td valign="middle" align="center" rowspan="1" colspan="1">52</td><td valign="middle" align="center" rowspan="1" colspan="1">29,7</td><td valign="middle" align="center" rowspan="1" colspan="1">0,3388</td></tr><tr><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>DRC</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Sim</td><td valign="middle" align="center" rowspan="1" colspan="1">24</td><td valign="middle" align="center" rowspan="1" colspan="1">37,5</td><td valign="middle" align="center" rowspan="1" colspan="1">54</td><td valign="middle" align="center" rowspan="1" colspan="1">30,9</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">N&#x000e3;o</td><td valign="middle" align="center" rowspan="1" colspan="1">40</td><td valign="middle" align="center" rowspan="1" colspan="1">62,5</td><td valign="middle" align="center" rowspan="1" colspan="1">121</td><td valign="middle" align="center" rowspan="1" colspan="1">69,1</td><td valign="middle" align="center" rowspan="1" colspan="1">0,3321</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Espironolactona</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Sim</td><td valign="middle" align="center" rowspan="1" colspan="1">8</td><td valign="middle" align="center" rowspan="1" colspan="1">12,5</td><td valign="middle" align="center" rowspan="1" colspan="1">15</td><td valign="middle" align="center" rowspan="1" colspan="1">8,6</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">N&#x000e3;o</td><td valign="middle" align="center" rowspan="1" colspan="1">56</td><td valign="middle" align="center" rowspan="1" colspan="1">87,5</td><td valign="middle" align="center" rowspan="1" colspan="1">161</td><td valign="middle" align="center" rowspan="1" colspan="1">92,0</td><td valign="middle" align="center" rowspan="1" colspan="1">0,3546</td></tr><tr><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Question&#x000e1;rio ADAM</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Negativo</td><td valign="middle" align="center" rowspan="1" colspan="1">4</td><td valign="middle" align="center" rowspan="1" colspan="1">6,3</td><td valign="middle" align="center" rowspan="1" colspan="1">20</td><td valign="middle" align="center" rowspan="1" colspan="1">11,4</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Positivo</td><td valign="middle" align="center" rowspan="1" colspan="1">51</td><td valign="middle" align="center" rowspan="1" colspan="1">79,7</td><td valign="middle" align="center" rowspan="1" colspan="1">133</td><td valign="middle" align="center" rowspan="1" colspan="1">76,0</td><td valign="middle" align="center" rowspan="1" colspan="1">0,2483</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Sem Informa&#x000e7;&#x000e3;o</td><td valign="middle" align="center" rowspan="1" colspan="1">9</td><td valign="middle" align="center" rowspan="1" colspan="1">14,1</td><td valign="middle" align="center" rowspan="1" colspan="1">22</td><td valign="middle" align="center" rowspan="1" colspan="1">12,6</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>N: n&#x000fa;mero total de indiv&#x000ed;duos no grupo amostral; n: frequ&#x000ea;ncia absoluta; f(%): frequ&#x000ea;ncia relativa percentual; HA: hipertens&#x000e3;o arterial; IMC: &#x000ed;ndice de massa corporal; DRC: doen&#x000e7;a renal cr&#x000f4;nica; Question&#x000e1;rio ADAM (do ingl&#x000ea;s, Androgen Deficiency, in the Aging Male).</p></fn><fn id="TFN3"><label>*</label><p>teste do qui-quadrado; teste exato de Fisher ou teste G.</p></fn></table-wrap-foot></table-wrap><p>Houve predom&#x000ed;nio de indiv&#x000ed;duos com obesidade no grupo de DT, IMC (&#x003c7;<sup>2</sup>=18,10; p=0,0001). Para a compara&#x000e7;&#x000e3;o entre as categorias de IMC, foram observadas diferen&#x000e7;as estatisticamente significantes entre: IMC normal e obeso (OR=6,62; IC95%=2,39&#x02013;18,32; p=0,0002), com acr&#x000e9;scimo de risco relativo de 32,1%; e sobrepeso e obeso (OR=2,41; IC95%=1,28&#x02013;4,54; p=0,0094), com acr&#x000e9;scimo de risco relativo de 18,9%. A
<xref rid="t3" ref-type="table">Tabela 3</xref>
mostra diferen&#x000e7;as estatisticamente significativas entre os grupos DT e eugon&#x000e1;dico nas vari&#x000e1;veis "tempo de HA" (p=0,317), "IMC" (p&#x0003c;0,0001) e "TT" (p&#x0003c;0,0001).</p><table-wrap position="float" id="t3"><label>Tabela 3</label><caption><title>
<italic toggle="yes">Mediana</italic>
e intervalo interquartil (
<italic toggle="yes">IIQ</italic>
) das vari&#x000e1;veis quantitativas cont&#x000ed;nuas de todos os 239 participantes e estratificadas e comparadas pelo status de testosterona. Goi&#x000e2;nia, Goi&#x000e1;s, Brasil, 2023</title></caption><table frame="hsides" rules="groups"><colgroup width="9%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000"><tr style="background-color:#76B4CF"><th valign="middle" align="left" rowspan="3" colspan="1">Vari&#x000e1;veis</th><th valign="middle" align="center" colspan="3" style="border-bottom: thin solid; border-color: #000000" rowspan="1">DT (n=64; 26,8%)</th><th valign="middle" align="center" colspan="3" style="border-left: thin solid; border-bottom: thin solid; border-color: #000000" rowspan="1">Eugon&#x000e1;dico (n=175; 73,2%)</th><th valign="middle" align="center" rowspan="3" style="border-left: thin solid; border-color: #000000" colspan="1">p-valor
<xref rid="TFN4a" ref-type="table-fn">*</xref></th><th valign="middle" align="center" colspan="3" style="border-left: thin solid; border-bottom: thin solid; border-color: #000000" rowspan="1">Total (N=239)</th></tr><tr style="background-color:#76B4CF"><th valign="middle" align="center" rowspan="2" colspan="1">
<italic toggle="yes">Mediana</italic>
</th><th valign="middle" align="center" colspan="2" style="border-bottom: thin solid; border-color: #000000" rowspan="1">
<italic toggle="yes">IIQ</italic>
</th><th valign="middle" align="center" rowspan="2" style="border-left: thin solid; border-color: #000000" colspan="1">
<italic toggle="yes">Mediana</italic>
</th><th valign="middle" align="center" colspan="2" style="border-bottom: thin solid; border-color: #000000" rowspan="1">
<italic toggle="yes">IIQ</italic>
</th><th valign="middle" align="center" rowspan="2" style="border-left: thin solid; border-color: #000000" colspan="1">
<italic toggle="yes">Mediana</italic>
</th><th valign="middle" align="center" colspan="2" style="border-bottom: thin solid; border-color: #000000" rowspan="1">
<italic toggle="yes">IIQ</italic>
</th></tr><tr style="background-color:#76B4CF"><th valign="middle" align="center" rowspan="1" colspan="1">25%</th><th valign="middle" align="center" rowspan="1" colspan="1">75%</th><th valign="middle" align="center" rowspan="1" colspan="1">25%</th><th valign="middle" align="center" rowspan="1" colspan="1">75%</th><th valign="middle" align="center" rowspan="1" colspan="1">25%</th><th valign="middle" align="center" rowspan="1" colspan="1">75%</th></tr></thead><tbody style="border-bottom: thin solid; border-color: #000000"><tr><td valign="middle" align="left" rowspan="1" colspan="1">Idade (anos)</td><td valign="middle" align="center" rowspan="1" colspan="1">63,5</td><td valign="middle" align="center" rowspan="1" colspan="1">58,8</td><td valign="middle" align="center" rowspan="1" colspan="1">70,0</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">62,0</td><td valign="middle" align="center" rowspan="1" colspan="1">55,0</td><td valign="middle" align="center" rowspan="1" colspan="1">70,5</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">0,3476</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">63,0</td><td valign="middle" align="center" rowspan="1" colspan="1">55,5</td><td valign="middle" align="center" rowspan="1" colspan="1">70,0</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1">Tempo de HA (anos)</td><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>16,5</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">8,0</td><td valign="middle" align="center" rowspan="1" colspan="1">24,3</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">
<bold>14,0</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">6,0</td><td valign="middle" align="center" rowspan="1" colspan="1">20,0</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">
<bold>0,0317</bold>
</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">15,0</td><td valign="middle" align="center" rowspan="1" colspan="1">7,0</td><td valign="middle" align="center" rowspan="1" colspan="1">20,0</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">N&#x000fa;mero de anti-hipertensivos</td><td valign="middle" align="center" rowspan="1" colspan="1">3,0</td><td valign="middle" align="center" rowspan="1" colspan="1">2,0</td><td valign="middle" align="center" rowspan="1" colspan="1">3,0</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">3,0</td><td valign="middle" align="center" rowspan="1" colspan="1">2,0</td><td valign="middle" align="center" rowspan="1" colspan="1">3,0</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">0,7242</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">3,0</td><td valign="middle" align="center" rowspan="1" colspan="1">2,0</td><td valign="middle" align="center" rowspan="1" colspan="1">3,0</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1">IMC (Kg/m<sup>2</sup>)</td><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>31,0</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">27,3</td><td valign="middle" align="center" rowspan="1" colspan="1">34,5</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">
<bold>27,7</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">24,9</td><td valign="middle" align="center" rowspan="1" colspan="1">30,8</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">
<bold>&#x0003c;0,0001</bold>
</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">28,5</td><td valign="middle" align="center" rowspan="1" colspan="1">25,4</td><td valign="middle" align="center" rowspan="1" colspan="1">31,6</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Testosterona total (ng/dL)</td><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>220,0</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">182,5</td><td valign="middle" align="center" rowspan="1" colspan="1">262,8</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">
<bold>449,0</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">360,0</td><td valign="middle" align="center" rowspan="1" colspan="1">532,0</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">
<bold>&#x0003c;0,0001</bold>
</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">376,7</td><td valign="middle" align="center" rowspan="1" colspan="1">286,3</td><td valign="middle" align="center" rowspan="1" colspan="1">491,5</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>DT: defici&#x000ea;ncia de testosterona; N: n&#x000fa;mero total de indiv&#x000ed;duos no grupo amostral; Mediana: medida de tend&#x000ea;ncia central; IIQ: intervalo interquartil de 25% e 75%; HA: hipertens&#x000e3;o arterial; IMC: &#x000ed;ndice de massa corporal.</p></fn><fn id="TFN4a"><label>*</label><p>Para gerar o p-valor, foi utilizado o teste de Mann-Whitney para amostras independentes.</p></fn></table-wrap-foot></table-wrap><p>A correla&#x000e7;&#x000e3;o de Spearman entre as vari&#x000e1;veis quantitativas cont&#x000ed;nuas demonstrou que os valores de TT tiveram rela&#x000e7;&#x000e3;o baixa, inversamente proporcional e estatisticamente significante com IMC (&#x003c1;=-0,26; p=0,0001), idade (&#x003c1;=-0,1760; p=0,0069) e tempo de diagn&#x000f3;stico de HA (&#x003c1;=-0,1410; p=0,0366) (
<xref rid="t4" ref-type="table">Tabela 4</xref>
).</p><table-wrap position="float" id="t4"><label>Tabela 4</label><caption><title>Correla&#x000e7;&#x000e3;o de Spearman entre as vari&#x000e1;veis quantitativas cont&#x000ed;nuas; Goi&#x000e2;nia Brasil, 2023</title></caption><table frame="hsides" rules="groups"><colgroup width="14%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000"><tr style="background-color:#76B4CF"><th valign="middle" align="left" colspan="2" rowspan="1">Vari&#x000e1;veis</th><th valign="middle" align="center" rowspan="1" colspan="1">Testosterona (ng/dL)</th><th valign="middle" align="center" rowspan="1" colspan="1">Idade (anos)</th><th valign="middle" align="center" rowspan="1" colspan="1">HA (anos)</th><th valign="middle" align="center" rowspan="1" colspan="1">Anti-hipertensivo</th><th valign="middle" align="center" rowspan="1" colspan="1">IMC (kg/m<sup>2</sup>)</th></tr></thead><tbody style="border-bottom: thin solid; border-color: #000000"><tr><td valign="middle" align="left" rowspan="2" colspan="1">Testosterona</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x003c1; (rho)</td><td valign="middle" align="center" rowspan="1" colspan="1">1,0000</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">p-valor</italic>
</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="2" colspan="1">Idade (anos)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x003c1; (rho)</td><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>-0,1760</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">1,0000</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">p-valor</italic>
</td><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>0,0068</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="2" colspan="1">HA (anos)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x003c1; (rho)</td><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>-0,1410</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>0,3530</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">1,0000</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">p-valor</italic>
</td><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>0,0366</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0,0001</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="2" colspan="1">Anti-hipertensivo</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x003c1; (rho)</td><td valign="middle" align="center" rowspan="1" colspan="1">-0,1046</td><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>0,1700</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>0,2640</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">1,0000</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">p-valor</italic>
</td><td valign="middle" align="center" rowspan="1" colspan="1">0,1083</td><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>0,0083</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>0,0001</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="2" colspan="1">IMC (kg/m<sup>2</sup>)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x003c1; (rho)</td><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>-0,2600</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>-0,2330</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">-0,0048</td><td valign="middle" align="center" rowspan="1" colspan="1">0,0521</td><td valign="middle" align="center" rowspan="1" colspan="1">1,0000</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">p-valor</italic>
</td><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>0,0001</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>0,0003</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">0,9434</td><td valign="middle" align="center" rowspan="1" colspan="1">0,4248</td><td valign="middle" align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TFN5"><p>HA: hipertens&#x000e3;o arterial; IMC: &#x000ed;ndice de massa corporal.</p></fn></table-wrap-foot></table-wrap><p>A
<xref rid="f1" ref-type="fig">Figura 1</xref>
descreve as vari&#x000e1;veis com diferen&#x000e7;a estatisticamente significante: (a) TT; (b) IMC e (c) tempo de diagn&#x000f3;stico de HA. Os indiv&#x000ed;duos com DT apresentaram medianas de TT de 222,0 ng/dL, IMC 31,0 kg/m<sup>2</sup> e 16,5 anos de diagn&#x000f3;stico de HA, enquanto os eugon&#x000e1;dicos apresentaram medianas de TT de 449,0 ng/dL, IMC 27,7 Kg/m<sup>2</sup> e 14,0 anos de diagn&#x000f3;stico de HA.</p><fig position="float" id="f1"><label>Figura 1</label><caption><title>Gr&#x000e1;ficos de diagrama de caixa, com mediana, intervalo interquartil (25% e 75%), valores m&#x000ed;nimo e m&#x000e1;ximo, das vari&#x000e1;veis com diferen&#x000e7;a estatisticamente significante: (a) testosterona total; (b) IMC e (c) tempo de diagn&#x000f3;stico de hipertens&#x000e3;o arterial. Goi&#x000e2;nia, Goi&#x000e1;s, Brasil.</title></caption><graphic xlink:href="0066-782X-abc-121-03-e20230138-gf01" position="float"/></fig><p>Foi realizada regress&#x000e3;o linear multivariada com as vari&#x000e1;veis com p-valores baixos (p&#x0003c;0,20), haja vista que todos os pressupostos estat&#x000ed;sticos (linearidade, independ&#x000ea;ncia, homoscedasticidade, normalidade dos res&#x000ed;duos, n&#x000e3;o colinearidade e aus&#x000ea;ncia de outliers) foram observados. As vari&#x000e1;veis que mais influenciaram a TT foram: o IMC e a idade. O acr&#x000e9;scimo de um ano de idade gerou decr&#x000e9;scimo de 3,79 ng/dL na TT (
<italic toggle="yes">B</italic>
=-3,79; IC95%=-5,57 at&#x000e9; -2,06; p&#x0003c;0,0001) e o aumento de um kg/m<sup>2</sup> no IMC gerou diminui&#x000e7;&#x000e3;o de 8,44 ng/dL na TT (
<italic toggle="yes">B</italic>
=-8,44; IC95%= -12,57 at&#x000e9; -4,32; p&#x0003c;0,0001) (
<xref rid="f2" ref-type="fig">Figura 2</xref>
).</p><fig position="float" id="f2"><label>Figura 2</label><caption><title>Rela&#x000e7;&#x000e3;o entre n&#x000ed;vel de testosterona total (em ng/dL) e o &#x000ed;ndice de massa corporal (IMC, em kg/m<sup>2</sup>), com todos os participantes (N=239).</title></caption><graphic xlink:href="0066-782X-abc-121-03-e20230138-gf02" position="float"/></fig></sec><sec sec-type="discussion"><title>Discuss&#x000e3;o</title><p>Ao nosso conhecimento, este &#x000e9; o primeiro estudo que avaliou a preval&#x000ea;ncia de DT em uma popula&#x000e7;&#x000e3;o especificamente hipertensa. Encontramos a preval&#x000ea;ncia de DT de 26,8%, e observou-se associa&#x000e7;&#x000e3;o de DT com o IMC (p=0,0007).</p><p>A obesidade &#x000e9; a condi&#x000e7;&#x000e3;o cl&#x000ed;nica mais fortemente associada &#x000e0; diminui&#x000e7;&#x000e3;o das concentra&#x000e7;&#x000f5;es de T entre os homens.<sup>
<xref rid="B19" ref-type="bibr">19</xref>
,
<xref rid="B20" ref-type="bibr">20</xref>
</sup> O excesso de peso promove supress&#x000e3;o do eixo HHT de car&#x000e1;ter funcional e potencialmente revers&#x000ed;vel.19 Baixos n&#x000ed;veis de T levam ao crescimento da adiposidade devido &#x000e0; aus&#x000ea;ncia do sinal inibidor na adipog&#x000ea;nese e na capta&#x000e7;&#x000e3;o lip&#x000ed;dica, mediado pela enzima lipoprote&#x000ed;na lipase, sobretudo em dep&#x000f3;sitos abdominais viscerais.<sup>
<xref rid="B21" ref-type="bibr">21</xref>
</sup> Por outro lado, a perda de peso pode levar &#x000e0; melhoria da fun&#x000e7;&#x000e3;o gonadal; assim, a rela&#x000e7;&#x000e3;o entre o excesso de peso e os n&#x000ed;veis de T &#x000e9; bidirecional, configurando c&#x000ed;rculo vicioso.<sup>
<xref rid="B21" ref-type="bibr">21</xref>
</sup> Neste estudo, as sub-an&#x000e1;lises de categorias de IMC mostraram que o aumento de peso normal para obeso acrescentou risco relativo de 32,1% de desenvolvimento de DT, enquanto que de sobrepeso para obeso acrescentou risco relativo de 18,9%. Al&#x000e9;m disso, o aumento de 1 kg/m<sup>2</sup> no IMC gerou queda de 8,44 ng/dL na TT (B=-8,44; IC95%= -12,57 at&#x000e9; -4,32; p&#x0003c;0,0001).</p><p>Existe um decl&#x000ed;nio natural dos horm&#x000f4;nios sexuais masculinos de aproximadamente 1% ao ano com o envelhecimento, entre as idades de 40 e 70 anos.<sup>
<xref rid="B22" ref-type="bibr">22</xref>
</sup> A preval&#x000ea;ncia de hipogonadismo de in&#x000ed;cio tardio ("
<italic toggle="yes">Late onset hypogonadism</italic>
"), associa-se n&#x000e3;o s&#x000f3; ao envelhecimento, como tamb&#x000e9;m com aumento o no IMC e nas doen&#x000e7;as coexistentes.22 Nesse sentido, este estudo buscou correlacionar o avan&#x000e7;ar da idade com a diminui&#x000e7;&#x000e3;o dos n&#x000ed;veis de TT. Contudo, o valor de p, embora marginal, n&#x000e3;o foi estatisticamente significante (p=0,0520). No entanto, a idade mostrou-se uma vari&#x000e1;vel significativa para a queda de TT na an&#x000e1;lise multivariada realizada, sendo que o acr&#x000e9;scimo de um ano na idade gerou decr&#x000e9;scimo de 3,79 ng/dL na TT (
<italic toggle="yes">B</italic>
=-3,79; IC95%=-5,57 at&#x000e9; -2,06; p&#x0003c;0,0001). Tais achados possivelmente seriam mais eloquentes em uma amostra maior.</p><p>Svartberg et al.<sup>
<xref rid="B7" ref-type="bibr">7</xref>
</sup> estudaram a press&#x000e3;o arterial em 1548 homens e os valores de TT foram inversamente associados &#x000e0; press&#x000e3;o arterial sist&#x000f3;lica (p&#x0003c;0,001) e &#x000e0; massa ventricular esquerda (p&#x0003c;0,001). Por&#x000e9;m, ap&#x000f3;s o ajuste para o IMC, os resultados sugeriram que essa rela&#x000e7;&#x000e3;o foi mediada pela obesidade.7 Zitzmann e Nieschlag<sup>
<xref rid="B23" ref-type="bibr">23</xref>
</sup> encontraram rela&#x000e7;&#x000f5;es semelhantes, sendo que a reposi&#x000e7;&#x000e3;o de T resultou em decr&#x000e9;scimos significativos desses par&#x000e2;metros e da frequ&#x000ea;ncia card&#x000ed;aca. Partindo desse racional, este estudo buscou associa&#x000e7;&#x000f5;es entre os valores de TT e os fatores tempo de diagn&#x000f3;stico de HA (p=0,1418) e o n&#x000fa;mero de classes de anti-hipertensivos usados (p=0,0732). Por&#x000e9;m, os achados n&#x000e3;o apresentaram signific&#x000e2;ncia estat&#x000ed;stica, o que talvez se justifique pelo fato de os fatores aqui pesquisados, embora in&#x000e9;ditos na literatura e indiretamente relacionados aos valores de press&#x000e3;o arterial propriamente ditos, difiram desses em &#x000fa;ltima an&#x000e1;lise.</p><p>A espironolactona &#x000e9; um anti-hipertensivo com propriedade anti-androg&#x000ea;nica por m&#x000fa;ltiplos mecanismos.<sup>
<xref rid="B24" ref-type="bibr">24</xref>
</sup> Por isso, investigamos se o seu emprego no tratamento da HA poderia ser um fator de confus&#x000e3;o ao se associar com a diminui&#x000e7;&#x000e3;o dos valores de TT, o que n&#x000e3;o foi confirmado (
<italic toggle="yes">p</italic>
=0,3546) em nossa amostra.</p><p>O quadro cl&#x000ed;nico do DT pode ser negligenciado, pois muitas vezes simula queixas condizentes com o envelhecimento ou com outras comorbidades.<sup>
<xref rid="B22" ref-type="bibr">22</xref>
</sup> O question&#x000e1;rio de defici&#x000ea;ncia de andr&#x000f3;genos da Universidade de Saint Louis (ADAM)<sup>
<xref rid="B13" ref-type="bibr">13</xref>
</sup> &#x000e9; amplamente utilizado como ferramenta de triagem para detectar homens em risco de defici&#x000ea;ncia androg&#x000ea;nica.<sup>
<xref rid="B16" ref-type="bibr">16</xref>
</sup> Neste estudo, por&#x000e9;m, n&#x000e3;o foi observada correla&#x000e7;&#x000e3;o entre n&#x000ed;vel de TT e question&#x000e1;rio ADAM positivo neste estudo (p=0,2483). Em nossa amostra, apenas 10% dos indiv&#x000ed;duos apresentaram question&#x000e1;rio ADAM negativo, o que possivelmente se justifica pelo fato de a HA estar associada &#x000e0; presen&#x000e7;a de queixas interrogadas no question&#x000e1;rio, fazendo, assim, com que ele perdesse especificidade.</p><p>A disfun&#x000e7;&#x000e3;o testicular atinge cerca de 50% dos homens com DRC,<sup>
<xref rid="B12" ref-type="bibr">12</xref>
</sup> com diferentes est&#x000e1;gios,<sup>
<xref rid="B24" ref-type="bibr">24</xref>
</sup> sendo associada ao aumento da mortalidade por todas as causas nessa popula&#x000e7;&#x000e3;o.<sup>
<xref rid="B25" ref-type="bibr">25</xref>
</sup> Assim, n&#x000f3;s avaliamos se a presen&#x000e7;a de DRC estaria associada &#x000e0; DT, o que n&#x000e3;o se confirmou neste estudo (
<italic toggle="yes">p</italic>
=0,3321). Tal fato poderia estar relacionado ao fato de que a maioria (93,5%) dos pacientes com DRC deste estudo apresentaram taxa de filtra&#x000e7;&#x000e3;o glomerular superior &#x000e0; 30 mL/min/1,72m<sup>2</sup>.</p><p>Os n&#x000ed;veis s&#x000e9;ricos de T tamb&#x000e9;m se relacionam com o metabolismo lip&#x000ed;dico, havendo rela&#x000e7;&#x000e3;o inversa entre valores de T e triglicer&#x000ed;deos, colesterol total e colesterol LDL, enquanto bons n&#x000ed;veis de T acompanham-se de HDL com valores normais.<sup>
<xref rid="B26" ref-type="bibr">26</xref>
</sup> Schiffer et al.<sup>
<xref rid="B27" ref-type="bibr">27</xref>
</sup> observaram que indiv&#x000ed;duos expostos &#x000e0; terapia de priva&#x000e7;&#x000e3;o androg&#x000ea;nica apresentam quadro de DLP. Neste estudo, n&#x000e3;o observamos correla&#x000e7;&#x000e3;o estatisticamente significante entre a presen&#x000e7;a de DLP e DT (p=0,3388), o que talvez pode ser explicado pelo fato de a nossa amostra ser de pacientes intensamente tratados.</p><p>Aproximadamente um ter&#x000e7;o dos portadores de DM tipo 2 (DM2) tem baixos n&#x000ed;veis de T.<sup>
<xref rid="B28" ref-type="bibr">28</xref>
</sup> Oh et al.<sup>
<xref rid="B29" ref-type="bibr">29</xref>
</sup> apontam a DT como um poss&#x000ed;vel fator de risco ao desenvolvimento de DM2. Homens com valores altos de T apresentam risco 42% menor de DM2, indicando que n&#x000ed;veis elevados do horm&#x000f4;nio sejam fator de prote&#x000e7;&#x000e3;o ao desenvolvimento de DM2.<sup>
<xref rid="B30" ref-type="bibr">30</xref>
</sup> Em nosso estudo, por&#x000e9;m, a presen&#x000e7;a de DM n&#x000e3;o apresentou correla&#x000e7;&#x000e3;o significativa com DT (
<italic toggle="yes">p</italic>
=0,1112). Isso pode ser reflexo da heterogeneidade da nossa popula&#x000e7;&#x000e3;o, com controle glic&#x000ea;mico e intensidade de tratamento variados, sendo que 19,5% dos pacientes com DM da amostra apresentavam classifica&#x000e7;&#x000e3;o de pr&#x000e9;-diabetes,<sup>
<xref rid="B10" ref-type="bibr">10</xref>
</sup> e poucos pacientes em insulinoterapia.</p><p>A T &#x000e9; o principal horm&#x000f4;nio sexual masculino<sup>
<xref rid="B22" ref-type="bibr">22</xref>
</sup> e desempenha papel crucial na sa&#x000fa;de reprodutiva, assim como na sa&#x000fa;de geral e na qualidade de vida do indiv&#x000ed;duo.15 As evid&#x000ea;ncias atuais apoiam fortemente a premissa de que baixo n&#x000ed;vel de T &#x000e9; importante biomarcador de morbimortalidade em homens,<sup>
<xref rid="B31" ref-type="bibr">31</xref>
</sup> sendo as consequ&#x000ea;ncias metab&#x000f3;licas mais adversas quanto mais baixa a T.<sup>
<xref rid="B21" ref-type="bibr">21</xref>
</sup></p><p>Quando a T &#x000e9; produzida, passa a circular ligada &#x000e0; globulina de liga&#x000e7;&#x000e3;o a horm&#x000f4;nio sexual (SHBG) e &#x000e0; albumina, sendo que apenas pequena fra&#x000e7;&#x000e3;o da T, de aproximadamente 2%, circula livremente como "Testosterona Livre" (TL),15 que corresponde &#x000e0; sua forma ativa. As concentra&#x000e7;&#x000f5;es da SHBG variam em fun&#x000e7;&#x000e3;o de fatores como idade, obesidade e outras doen&#x000e7;as cr&#x000f4;nicas.<sup>
<xref rid="B32" ref-type="bibr">32</xref>
</sup></p><p>Esta pesquisa foi um estudo de vida real. Entre suas limita&#x000e7;&#x000f5;es consta o fato de os exames bioqu&#x000ed;micos terem sido realizados de forma rand&#x000f4;mica e em sua maioria na rede p&#x000fa;blica de sa&#x000fa;de e, por isso, n&#x000e3;o houve uniformidade entre os m&#x000e9;todos laboratoriais empregados. Al&#x000e9;m disso, os valores de TL n&#x000e3;o terem sido avaliados, devido aos custos envolvidos com os exames que permitiriam seu c&#x000e1;lculo indireto.<sup>
<xref rid="B15" ref-type="bibr">15</xref>
</sup></p><p>Este &#x000e9; o primeiro estudo, ao nosso conhecimento, que buscou demonstrar a preval&#x000ea;ncia de DT em uma popula&#x000e7;&#x000e3;o especificamente hipertensa. O potencial delet&#x000e9;rio da defici&#x000ea;ncia androg&#x000ea;nica &#x000e9; possivelmente inntensificado em um contexto de maior risco cardiovascular, o que nos alertaria sobre a import&#x000e2;ncia de seu reconhecimento. A preval&#x000ea;ncia crescente da obesidade hoje refor&#x000e7;a a necessidade de estrat&#x000e9;gias que promovam seu controle, sobretudo entre homens hipertensos, pois suas repercuss&#x000f5;es podem impactar em v&#x000e1;rios aspectos, dentre eles sua sa&#x000fa;de sexual, fertilidade e qualidade de vida.</p></sec><sec sec-type="conclusions"><title>Conclus&#x000f5;es</title><p>O estudo encontrou alta preval&#x000ea;ncia de DT (26,8%) em pacientes hipertensos
<bold>,</bold>
sem, contudo, demonstrar associa&#x000e7;&#x000e3;o entre n&#x000ed;vel de TT e tempo de diagn&#x000f3;stico de HA, n&#x000fa;mero de classe de anti-hipertensivos, uso de espironolactona, sintomas positivos de DT, presen&#x000e7;a de DM, DLP, e DRC. Por&#x000e9;m, houve forte associa&#x000e7;&#x000e3;o inversa da TT com o IMC, sendo que o aumento do IMC em uma unidade se associou &#x000e0; queda em nos valores de TT em 8.44 ng/dL; assim como o avan&#x000e7;o em um ano na idade associou-se ao seu decl&#x000ed;nio em 3,79 ng/dL. Novos estudos s&#x000e3;o necess&#x000e1;rios a fim de elucidar a poss&#x000ed;vel associa&#x000e7;&#x000e3;o entre a HA e DT.</p></sec></body><back><ack><title>Agradecimentos</title><p>Agradecemos &#x000e0;s secret&#x000e1;rias da Liga de Hipertens&#x000e3;o Arterial, Beatriz dos Santos e Cl&#x000e1;udia Zorzetti, cujas colabora&#x000e7;&#x000f5;es foram cruciais para a realiza&#x000e7;&#x000e3;o deste estudo.</p></ack><fn-group><fn fn-type="financial-disclosure" id="fn1"><p>
<bold>Fontes de financiamento</bold>
</p><p>O presente estudo n&#x000e3;o teve fontes de financiamento externas.</p></fn><fn fn-type="other" id="fn2"><p>
<bold>Vincula&#x000e7;&#x000e3;o acad&#x000ea;mica</bold>
</p><p>Este artigo &#x000e9; parte de tese de doutorado de Leandra Analia Freitas Negretto pela Universidade Federal de Goi&#x000e1;s.</p></fn><fn fn-type="other" id="fn3"><p>
<bold>Aprova&#x000e7;&#x000e3;o &#x000e9;tica e consentimento informado</bold>
</p><p>Este estudo foi aprovado pelo Comit&#x000ea; de &#x000c9;tica do Hospital das Cl&#x000ed;nicas da Universidade Federal de Goi&#x000e1;s &#x02013; CEP/HC/UFG sob o n&#x000fa;mero de protocolo 2.552.801. Todos os procedimentos envolvidos nesse estudo est&#x000e3;o de acordo com a Declara&#x000e7;&#x000e3;o de Helsinki de 1975, atualizada em 2013. O consentimento informado foi obtido de todos os participantes inclu&#x000ed;dos no estudo.</p></fn><fn id="fn4" fn-type="other"><p>Editor respons&#x000e1;vel pela revis&#x000e3;o: Gl&#x000e1;ucia Maria Moraes de Oliveira</p></fn></fn-group><ref-list><title>Refer&#x000ea;ncias</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhasin</surname><given-names>S</given-names></name>
<name><surname>Brito</surname><given-names>JP</given-names></name>
<name><surname>Cunningham</surname><given-names>GR</given-names></name>
<name><surname>Hayes</surname><given-names>FJ</given-names></name>
<name><surname>Hodis</surname><given-names>HN</given-names></name>
<name><surname>Matsumoto</surname><given-names>AM</given-names></name>
<etal/>
</person-group><article-title>Testosterone Therapy in Men with Hypogonadism: an Endocrine Society Clinical Practice Guideline</article-title><source>
J Clin Endocrinol Metab
</source><year>2018</year><volume>103</volume><issue>5</issue><fpage>1715</fpage><lpage>1744</lpage><pub-id pub-id-type="doi">10.1210/jc.2018-00229</pub-id><pub-id pub-id-type="pmid">29562364</pub-id>
</element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feldman</surname><given-names>HA</given-names></name>
<name><surname>Longcope</surname><given-names>C</given-names></name>
<name><surname>Derby</surname><given-names>CA</given-names></name>
<name><surname>Johannes</surname><given-names>CB</given-names></name>
<name><surname>Araujo</surname><given-names>AB</given-names></name>
<name><surname>Coviello</surname><given-names>AD</given-names></name>
<etal/>
</person-group><article-title>Age Trends in the Level of Serum Testosterone and Other Hormones in Middle-Aged Men: Longitudinal Results from the Massachusetts Male Aging Study</article-title><source>
J Clin Endocrinol Metab
</source><year>2002</year><volume>87</volume><issue>2</issue><fpage>589</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1210/jcem.87.2.8201</pub-id><pub-id pub-id-type="pmid">11836290</pub-id>
</element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kelleher</surname><given-names>S</given-names></name>
<name><surname>Conway</surname><given-names>AJ</given-names></name>
<name><surname>Handelsman</surname><given-names>DJ</given-names></name>
</person-group><article-title>Blood Testosterone Threshold for Androgen Deficiency Symptoms</article-title><source>
J Clin Endocrinol Metab
</source><year>2004</year><volume>89</volume><issue>8</issue><fpage>3813</fpage><lpage>3817</lpage><pub-id pub-id-type="doi">10.1210/jc.2004-0143</pub-id><pub-id pub-id-type="pmid">15292310</pub-id>
</element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhasin</surname><given-names>S</given-names></name>
<name><surname>Cunningham</surname><given-names>GR</given-names></name>
<name><surname>Hayes</surname><given-names>FJ</given-names></name>
<name><surname>Matsumoto</surname><given-names>AM</given-names></name>
<name><surname>Snyder</surname><given-names>PJ</given-names></name>
<name><surname>Swerdloff</surname><given-names>RS</given-names></name>
<etal/>
</person-group><article-title>Testosterone Therapy in Men with Androgen Deficiency Syndromes: an Endocrine Society Clinical Practice Guideline</article-title><source>
J Clin Endocrinol Metab
</source><year>2010</year><volume>95</volume><issue>6</issue><fpage>2536</fpage><lpage>2559</lpage><pub-id pub-id-type="doi">10.1210/jc.2009-2354</pub-id><pub-id pub-id-type="pmid">20525905</pub-id>
</element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shores</surname><given-names>MM</given-names></name>
<name><surname>Matsumoto</surname><given-names>AM</given-names></name>
<name><surname>Sloan</surname><given-names>KL</given-names></name>
<name><surname>Kivlahan</surname><given-names>DR</given-names></name>
</person-group><article-title>Low Serum Testosterone and Mortality in Male Veterans</article-title><source>
Arch Intern Med
</source><year>2006</year><volume>166</volume><issue>15</issue><fpage>1660</fpage><lpage>1665</lpage><pub-id pub-id-type="doi">10.1001/archinte.166.15.1660</pub-id><pub-id pub-id-type="pmid">16908801</pub-id>
</element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mulligan</surname><given-names>T</given-names></name>
<name><surname>Frick</surname><given-names>MF</given-names></name>
<name><surname>Zuraw</surname><given-names>QC</given-names></name>
<name><surname>Stemhagen</surname><given-names>A</given-names></name>
<name><surname>McWhirter</surname><given-names>C.</given-names></name>
</person-group><article-title>Prevalence of Hypogonadism in Males Aged at Least 45 Years: the HIM Study</article-title><source>
Int J Clin Pract
</source><year>2006</year><volume>60</volume><issue>7</issue><fpage>762</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1111/j.1742-1241.2006.00992.x</pub-id><pub-id pub-id-type="pmid">16846397</pub-id>
</element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Svartberg</surname><given-names>J</given-names></name>
<name><surname>von M&#x000fc;hlen</surname><given-names>D</given-names></name>
<name><surname>Schirmer</surname><given-names>H</given-names></name>
<name><surname>Barrett-Connor</surname><given-names>E</given-names></name>
<name><surname>Sundfjord</surname><given-names>J</given-names></name>
<name><surname>Jorde</surname><given-names>R.</given-names></name>
</person-group><article-title>Association of Endogenous Testosterone with Blood Pressure and Left Ventricular Mass in Men</article-title><source>
The Troms&#x000f8; Study. Eur J Endocrinol
</source><year>2004</year><volume>150</volume><issue>1</issue><fpage>65</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1530/eje.0.1500065</pub-id><pub-id pub-id-type="pmid">14713281</pub-id>
</element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>MR</given-names></name>
<name><surname>Lee</surname><given-names>H</given-names></name>
<name><surname>Nathan</surname><given-names>DM</given-names></name>
</person-group><article-title>Insulin Sensitivity During Combined Androgen Blockade for Prostate Cancer</article-title><source>
J Clin Endocrinol Metab
</source><year>2006</year><volume>91</volume><issue>4</issue><fpage>1305</fpage><lpage>1308</lpage><pub-id pub-id-type="doi">10.1210/jc.2005-2507</pub-id><pub-id pub-id-type="pmid">16434464</pub-id>
</element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="book"><article-title>Associa&#x000e7;&#x000e3;o Brasileira para o Estudo da Obesidade e da S&#x000ed;ndrome Metab&#x000f3;lica</article-title><source>
Diretrizes Brasileiras de Obesidade
</source><edition>4nd ed.</edition><publisher-loc>S&#x000e3;o Paulo</publisher-loc><publisher-name>The Association</publisher-name><year>2016</year></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Sociedade Brasileira de Diabetes</collab>
</person-group><source>
Diretrizes da Sociedade Brasileira de Diabetes 2019-2020
</source><publisher-loc>Bras&#x000ed;lia</publisher-loc><publisher-name>Clannad</publisher-name><year>2019</year></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Faludi</surname><given-names>AA</given-names></name>
<name><surname>Izar</surname><given-names>MC</given-names></name>
<name><surname>Saraiva</surname><given-names>JF</given-names></name>
<name><surname>Chacra</surname><given-names>AP</given-names></name>
<name><surname>Bianco</surname><given-names>HT</given-names></name>
<name><surname>Afiune</surname><given-names>A</given-names><suffix>Neto</suffix></name>
<etal/>
</person-group><article-title>Atualiza&#x000e7;&#x000e3;o da Diretriz Brasileira de Dislipidemias e Preven&#x000e7;&#x000e3;o da Aterosclerose &#x02013; 2017</article-title><source>
Arq Bras Cardiol
</source><year>2017</year><volume>109</volume><issue>2</issue><fpage>1</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.5935/abc.20170121</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Willis</surname><given-names>K</given-names></name>
<name><surname>Cheung</surname><given-names>M</given-names></name>
<name><surname>Slifer</surname><given-names>S</given-names></name>
</person-group><article-title>International Society of Nephrology. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease</article-title><source>
Kidney Int Suppl
</source><year>2013</year><volume>3</volume><issue>1</issue><fpage>1</fpage><lpage>163</lpage></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morley</surname><given-names>JE</given-names></name>
<name><surname>Charlton</surname><given-names>E</given-names></name>
<name><surname>Patrick</surname><given-names>P</given-names></name>
<name><surname>Kaiser</surname><given-names>FE</given-names></name>
<name><surname>Cadeau</surname><given-names>P</given-names></name>
<name><surname>McCready</surname><given-names>D</given-names></name>
<etal/>
</person-group><article-title>Validation of a Screening Questionnaire for Androgen Deficiency in Aging Males</article-title><source>
Metabolism
</source><year>2000</year><volume>49</volume><issue>9</issue><fpage>1239</fpage><lpage>1242</lpage><pub-id pub-id-type="doi">10.1053/meta.2000.8625</pub-id><pub-id pub-id-type="pmid">11016912</pub-id>
</element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mulhall</surname><given-names>JP</given-names></name>
<name><surname>Trost</surname><given-names>LW</given-names></name>
<name><surname>Brannigan</surname><given-names>RE</given-names></name>
<name><surname>Kurtz</surname><given-names>EG</given-names></name>
<name><surname>Redmon</surname><given-names>JB</given-names></name>
<name><surname>Chiles</surname><given-names>KA</given-names></name>
<etal/>
</person-group><article-title>Evaluation and Management of Testosterone Deficiency: AUA Guideline</article-title><source>
J Urol
</source><year>2018</year><volume>200</volume><issue>2</issue><fpage>423</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2018.03.115</pub-id><pub-id pub-id-type="pmid">29601923</pub-id>
</element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kanakis</surname><given-names>GA</given-names></name>
<name><surname>Tsametis</surname><given-names>CP</given-names></name>
<name><surname>Goulis</surname><given-names>DG</given-names></name>
</person-group><article-title>Measuring Testosterone in Women and Men</article-title><source>
Maturitas
</source><year>2019</year><volume>125</volume><fpage>41</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.maturitas.2019.04.203</pub-id><pub-id pub-id-type="pmid">31133215</pub-id>
</element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mohamed</surname><given-names>O</given-names></name>
<name><surname>Freundlich</surname><given-names>RE</given-names></name>
<name><surname>Dakik</surname><given-names>HK</given-names></name>
<name><surname>Grober</surname><given-names>ED</given-names></name>
<name><surname>Najari</surname><given-names>B</given-names></name>
<name><surname>Lipshultz</surname><given-names>LI</given-names></name>
<etal/>
</person-group><article-title>The Quantitative ADAM Questionnaire: a New Tool in Quantifying the Severity of Hypogonadism</article-title><source>
Int J Impot Res
</source><year>2010</year><volume>22</volume><issue>1</issue><fpage>20</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/ijir.2009.35</pub-id><pub-id pub-id-type="pmid">19657348</pub-id>
</element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Sociedade Brasileira de Endocrinologia, Sociedade Brasileira de Urologia</collab>
</person-group><source>
Hipogonadismo Masculino Tardio ou Defici&#x000ea;ncia Androg&#x000ea;nica do Envelhecimento Masculino (DAEM): diagn&#x000f3;stico
</source><publisher-loc>Rio de Janeiro</publisher-loc><publisher-name>The Societies</publisher-name><year>2017</year></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Field</surname><given-names>A.</given-names></name>
</person-group><source>
Discovering Statistics with SPSS
</source><edition>2nd. ed.</edition><publisher-loc>Porto Alegre</publisher-loc><publisher-name>Artmed</publisher-name><year>2009</year></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grossmann</surname><given-names>M.</given-names></name>
</person-group><article-title>Hypogonadism and Male Obesity: Focus on Unresolved Questions</article-title><source>
Clin Endocrinol
</source><year>2018</year><volume>89</volume><issue>1</issue><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1111/cen.13723</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lamm</surname><given-names>S</given-names></name>
<name><surname>Chidakel</surname><given-names>A</given-names></name>
<name><surname>Bansal</surname><given-names>R.</given-names></name>
</person-group><article-title>Obesity and Hypogonadism</article-title><source>
Urol Clin North Am
</source><year>2016</year><volume>43</volume><issue>2</issue><fpage>239</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1016/j.ucl.2016.01.005</pub-id><pub-id pub-id-type="pmid">27132582</pub-id>
</element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carrageta</surname><given-names>DF</given-names></name>
<name><surname>Oliveira</surname><given-names>PF</given-names></name>
<name><surname>Alves</surname><given-names>MG</given-names></name>
<name><surname>Monteiro</surname><given-names>MP</given-names></name>
</person-group><article-title>Obesity and Male Hypogonadism: Tales of a Vicious Cycle</article-title><source>
Obes Rev
</source><year>2019</year><volume>20</volume><issue>8</issue><fpage>1148</fpage><lpage>1158</lpage><pub-id pub-id-type="doi">10.1111/obr.12863</pub-id><pub-id pub-id-type="pmid">31035310</pub-id>
</element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hochreiter</surname><given-names>WW</given-names></name>
<name><surname>Ackermann</surname><given-names>DK</given-names></name>
<name><surname>Br&#x000fc;tsch</surname><given-names>HP</given-names></name>
</person-group><article-title>Andropause</article-title><source>
Ther Umsch
</source><year>2005</year><volume>62</volume><issue>12</issue><fpage>821</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1024/0040-5930.62.12.821</pub-id><pub-id pub-id-type="pmid">16405287</pub-id>
</element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zitzmann</surname><given-names>M</given-names></name>
<name><surname>Nieschlag</surname><given-names>E.</given-names></name>
</person-group><article-title>Androgen Receptor Gene Cag Repeat Length and Body Mass Index Modulate the Safety of Long-Term Intramuscular Testosterone Undecanoate Therapy in Hypogonadal Men</article-title><source>
J Clin Endocrinol Metab
</source><year>2007</year><volume>92</volume><issue>10</issue><fpage>3844</fpage><lpage>3853</lpage><pub-id pub-id-type="doi">10.1210/jc.2007-0620</pub-id><pub-id pub-id-type="pmid">17635942</pub-id>
</element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bagnoli</surname><given-names>VR</given-names></name>
<name><surname>Fonseca</surname><given-names>AM</given-names></name>
<name><surname>Cezarino</surname><given-names>PY</given-names></name>
<name><surname>Fassolas</surname><given-names>G</given-names></name>
<name><surname>Arie</surname><given-names>JA</given-names></name>
<name><surname>Baracat</surname><given-names>EC</given-names></name>
</person-group><article-title>Tratamento Hormonal da Acne Baseado em Evid&#x000ea;ncias</article-title><source>
Femina
</source><year>2010</year><volume>38</volume><issue>11</issue><fpage>565</fpage><lpage>574</lpage></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khurana</surname><given-names>KK</given-names></name>
<name><surname>Navaneethan</surname><given-names>SD</given-names></name>
<name><surname>Arrigain</surname><given-names>S</given-names></name>
<name><surname>Schold</surname><given-names>JD</given-names></name>
<name><surname>Nally</surname><given-names>JV</given-names><suffix>Jr</suffix></name>
<name><surname>Shoskes</surname><given-names>DA</given-names></name>
</person-group><article-title>Serum Testosterone Levels and Mortality in Men with CKD Stages 3-4</article-title><source>
Am J Kidney Dis
</source><year>2014</year><volume>64</volume><issue>3</issue><fpage>367</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2014.03.010</pub-id><pub-id pub-id-type="pmid">24726629</pub-id>
</element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rastrelli</surname><given-names>G</given-names></name>
<name><surname>Filippi</surname><given-names>S</given-names></name>
<name><surname>Sforza</surname><given-names>A</given-names></name>
<name><surname>Maggi</surname><given-names>M</given-names></name>
<name><surname>Corona</surname><given-names>G.</given-names></name>
</person-group><article-title>Metabolic Syndrome in Male Hypogonadism</article-title><source>
Front Horm Res
</source><year>2018</year><volume>49</volume><fpage>131</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1159/000485999</pub-id><pub-id pub-id-type="pmid">29895018</pub-id>
</element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schiffer</surname><given-names>L</given-names></name>
<name><surname>Kempegowda</surname><given-names>P</given-names></name>
<name><surname>Arlt</surname><given-names>W</given-names></name>
<name><surname>O'Reilly</surname><given-names>MW</given-names></name>
</person-group><article-title>Mechanisms in Endocrinology: The Sexually Dimorphic Role of Androgens in Human Metabolic Disease</article-title><source>
Eur J Endocrinol
</source><year>2017</year><volume>177</volume><issue>3</issue><fpage>R125</fpage><lpage>R143</lpage><pub-id pub-id-type="doi">10.1530/EJE-17-0124</pub-id><pub-id pub-id-type="pmid">28566439</pub-id>
</element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dhindsa</surname><given-names>S</given-names></name>
<name><surname>Prabhakar</surname><given-names>S</given-names></name>
<name><surname>Sethi</surname><given-names>M</given-names></name>
<name><surname>Bandyopadhyay</surname><given-names>A</given-names></name>
<name><surname>Chaudhuri</surname><given-names>A</given-names></name>
<name><surname>Dandona</surname><given-names>P.</given-names></name>
</person-group><article-title>Frequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes</article-title><source>
J Clin Endocrinol Metab
</source><year>2004</year><volume>89</volume><issue>11</issue><fpage>5462</fpage><lpage>5468</lpage><pub-id pub-id-type="doi">10.1210/jc.2004-0804</pub-id><pub-id pub-id-type="pmid">15531498</pub-id>
</element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oh</surname><given-names>JY</given-names></name>
<name><surname>Barrett-Connor</surname><given-names>E</given-names></name>
<name><surname>Wedick</surname><given-names>NM</given-names></name>
<name><surname>Wingard</surname><given-names>DL</given-names></name>
</person-group><article-title>Endogenous Sex Hormones and the Development of Type 2 Diabetes in Older Men and Women: the Rancho Bernardo Study</article-title><source>
Diabetes Care
</source><year>2002</year><volume>25</volume><issue>1</issue><fpage>55</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.2337/diacare.25.1.55</pub-id><pub-id pub-id-type="pmid">11772901</pub-id>
</element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ding</surname><given-names>EL</given-names></name>
<name><surname>Song</surname><given-names>Y</given-names></name>
<name><surname>Malik</surname><given-names>VS</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
</person-group><article-title>Sex Differences of Endogenous Sex Hormones and Risk of Type 2 Diabetes: a Systematic Review and Meta-Analysis</article-title><source>
JAMA
</source><year>2006</year><volume>295</volume><issue>11</issue><fpage>1288</fpage><lpage>1299</lpage><pub-id pub-id-type="doi">10.1001/jama.295.11.1288</pub-id><pub-id pub-id-type="pmid">16537739</pub-id>
</element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zarotsky</surname><given-names>V</given-names></name>
<name><surname>Huang</surname><given-names>MY</given-names></name>
<name><surname>Carman</surname><given-names>W</given-names></name>
<name><surname>Morgentaler</surname><given-names>A</given-names></name>
<name><surname>Singhal</surname><given-names>PK</given-names></name>
<name><surname>Coffin</surname><given-names>D</given-names></name>
<etal/>
</person-group><article-title>Systematic Literature Review of the Risk Factors, Comorbidities, and Consequences of Hypogonadism in Men</article-title><source>
Andrology
</source><year>2014</year><volume>2</volume><issue>6</issue><fpage>819</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1111/andr.274</pub-id><pub-id pub-id-type="pmid">25269643</pub-id>
</element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bahia</surname><given-names>L</given-names></name>
<name><surname>Dimetz</surname><given-names>T</given-names></name>
<name><surname>Gazolla</surname><given-names>H</given-names></name>
<name><surname>Clemente</surname><given-names>E</given-names></name>
<name><surname>Gomes</surname><given-names>MB</given-names></name>
</person-group><article-title>Interrela&#x000e7;&#x000f5;es entre SHBG e Ester&#x000f3;ides Sexuais com Medidas Antropom&#x000e9;tricas, Press&#x000e3;o Arterial e Lip&#x000ed;deos em Mulheres com e sem Diabetes Mellitus tipo 2</article-title><source>
Arq Bras Endocrinol Metab
</source><year>2000</year><volume>44</volume><issue>3</issue><fpage>239</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1590/S0004-27302000000300009</pub-id></element-citation></ref></ref-list></back><sub-article article-type="translation" id="S01" xml:lang="en"><front-stub><article-id pub-id-type="doi">10.36660/abc.20230138i</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Testosterone Deficiency in Hypertensive Men: Prevalence and Associated Factors</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2678-4715</contrib-id><name><surname>Negretto</surname><given-names>Leandra Analia Freitas</given-names></name><role>Conception and design of the research</role><role>Analysis and interpretation of the data</role><role>Statistical analysis</role><role>Writing of the manuscript</role><role>Acquisition of data</role><role>Critical revision of the manuscript for important intellectual content</role><xref rid="aff3" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c2" ref-type="corresp"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0006-2145-3377</contrib-id><name><surname>Rassi</surname><given-names>Nelson</given-names></name><role>Critical revision of the manuscript for important intellectual content</role><xref rid="aff4" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Soares</surname><given-names>Leonardo Ribeiro</given-names></name><role>Critical revision of the manuscript for important intellectual content</role><xref rid="aff3" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Saraiva</surname><given-names>Amanda Bueno Carvalho</given-names></name><role>Acquisition of data</role><xref rid="aff3" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4785-9651</contrib-id><name><surname>Teixeira</surname><given-names>Maria Em&#x000ed;lia Figueiredo</given-names></name><role>Acquisition of data</role><xref rid="aff3" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Santos</surname><given-names>Luciana da Ressurrei&#x000e7;&#x000e3;o</given-names></name><role>Critical revision of the manuscript for important intellectual content</role><xref rid="aff3" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Souza</surname><given-names>Ana Luiza Lima</given-names></name><role>Critical revision of the manuscript for important intellectual content</role><xref rid="aff3" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5333-013X</contrib-id><name><surname>Jardim</surname><given-names>Paulo Cesar B. Veiga</given-names></name><role>Critical revision of the manuscript for important intellectual content</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Barroso de Souza</surname><given-names>Weimar Kunz Sebba</given-names></name><role>Critical revision of the manuscript for important intellectual content</role><xref rid="aff3" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jardim</surname><given-names>Thiago de Souza Veiga</given-names></name><role>Critical revision of the manuscript for important intellectual content</role><xref rid="aff3" ref-type="aff">
<sup>1</sup>
</xref></contrib><aff id="aff3">
<label>1</label>
<addr-line>
<named-content content-type="city">Goi&#x000e2;nia</named-content>
<named-content content-type="state">GO</named-content>
</addr-line>
<country country="BR">Brazil</country>
<institution content-type="original">Universidade Federal de Goi&#x000e1;s &#x02013; Liga de Hipertens&#x000e3;o Arterial, Goi&#x000e2;nia, GO &#x02013; Brazil</institution>
</aff><aff id="aff4">
<label>2</label>
<addr-line>
<named-content content-type="city">Goi&#x000e2;nia</named-content>
<named-content content-type="state">GO</named-content>
</addr-line>
<country country="BR">Brazil</country>
<institution content-type="original">Hospital Geral de Goi&#x000e2;nia &#x02013; Dr. Alberto Rassi, Goi&#x000e2;nia, GO &#x02013; Brazil</institution>
</aff></contrib-group><author-notes><corresp id="c2">
<bold>Mailing Address: Leandra Analia Freitas Negretto</bold>
&#x02022; Universidade Federal de Goi&#x000e1;s &#x02013; Liga de Hipertens&#x000e3;o Arterial &#x02013; 5 avenida, 7692. Postal Code
<postal-code>74605-220</postal-code>
, Setor Leste Universit&#x000e1;rio, Goi&#x000e2;nia, GO &#x02013; Brazil E-mail:
<email>lenegretto@gmail.com</email>
</corresp><fn fn-type="COI-statement"><p>
<bold>Potential conflict of interest</bold>
</p><p>No potential conflict of interest relevant to this article was reported.</p></fn></author-notes><abstract><title>Abstract</title><sec><title>Background:</title><p>Testosterone deficiency (TD) is a prevalent condition in our midst and still very neglected. Arterial hypertension (AH) is one of the possible associated factors.</p></sec><sec><title>Objectives:</title><p>To determine the prevalence of TD in a hypertensive male population and the factors associated with its occurrence, such as age, time since hypertension diagnosis, number of antihypertensive classes, body mass index (BMI), diabetes, dyslipidemia, chronic kidney disease (CKD), positive symptoms of TD (positive ADAM questionnaire) and use of spironolactone.</p></sec><sec><title>Methods:</title><p>Cross-sectional study with administration of the ADAM questionnaire, assessment of biochemical, clinical, and anthropometric data. Patients were stratified into DT and normal testosterone groups. Categorical variables were compared using the chi-squared test and continuous variables using the Mann-Witney test; variables with significance (p&#x0003c;0,05) were analyzed by multivariable linear regression.</p></sec><sec><title>Results:</title><p>The prevalence of TD was 26.36%. There was an association between TD and body mass index (BMI) (p=0.0007) but there was no association with age (p=0.0520), time of hypertension diagnosis (p=0.1418), number of classes of antihypertensive drugs (p=0.732), diabetes (p=0.1112); dyslipidemia (p=0.3888); CKD (p=0.3321); use of spironolactone (p=0.3546) or positive ADAM questionnaire (p=0.2483).</p></sec><sec><title>Conclusions:</title><p>TD was highly prevalent and positively associated with BMI. Total testosterone (TT) declined by 8.44ng/dL with a one unit increase in BMI and dropped by 3.79ng/dL with a one-year increase in age.</p></sec></abstract><kwd-group><title>Keywords:</title><kwd>Testosterone</kwd><kwd>Hypertension</kwd><kwd>Obesity</kwd><kwd>Hypogonadism</kwd></kwd-group></front-stub><body><fig position="float" id="f6"><graphic xlink:href="0066-782X-abc-121-03-e20230138-gf03-en" position="float"/></fig><sec sec-type="intro"><title>Introduction</title><p>Testosterone deficiency (TD) results from failure of the testes to produce physiological levels of testosterone (T) due to rupture in at least one of the elements of the hypothalamic-pituitary-testicular (HPT) axis. When TD is associated with clinical signs of androgen deficiency, the diagnosis of male hypogonadism may be established.<sup>
<xref rid="B1" ref-type="bibr">1</xref>
</sup>The prevalence of hypogonadism in male population varies with age, ranging from six to 12.3% between 40 and 69 years of age, respectively.<sup>
<xref rid="B2" ref-type="bibr">2</xref>
</sup></p><p>TD may cause different signs and symptoms that depend on age of onset and TD severity,<sup>
<xref rid="B3" ref-type="bibr">3</xref>
</sup>and include: reduced libido, erectile dysfunction, loss of body and facial hair, loss of lean mass, increase of fat mass, fatigue and anemia.<sup>
<xref rid="B3" ref-type="bibr">3</xref>
,
<xref rid="B4" ref-type="bibr">4</xref>
</sup>In addition, survival of men with low T levels is lower than of men with normal T levels (eugonadism), with an all-cause mortality of 34.9%
<italic toggle="yes">
<bold>vs.</bold>
</italic>
20.1%, respectively.<sup>
<xref rid="B5" ref-type="bibr">5</xref>
</sup></p><p>Hypertension has been associated with TD in previous studies, as in the "Hypogonadism in males" (HIM),<sup>
<xref rid="B6" ref-type="bibr">6</xref>
</sup>which showed that a higher proportion of hypogonadal patients was hypertensive as compared with eugonadal subjects. According to Svartberg et al.,<sup>
<xref rid="B7" ref-type="bibr">7</xref>
</sup>hypertensive individuals have lower baseline T levels than nonhypertensive ones, regardless of age. Smith et al.<sup>
<xref rid="B8" ref-type="bibr">8</xref>
</sup>showed that androgen deprivation therapy for prostate cancer could induce hypertension.</p><p>The relationship between hypertension and TD has many gaps, including epidemiological, diagnostic, and therapeutic issues. In this context, the aim of this study was to determine the prevalence of TD in a cohort of hypertensive men seen at a referral hypertension center in Brazil. Also, the study evaluated, in this population, factors related to its occurrence &#x02013; age, time of diagnosis of hypertension, number of antihypertensive classes, body mass index (BMI),<sup>
<xref rid="B9" ref-type="bibr">9</xref>
</sup>presence of diabetes mellitus (DM),<sup>
<xref rid="B10" ref-type="bibr">10</xref>
</sup>dyslipidemia (DLP),<sup>
<xref rid="B11" ref-type="bibr">11</xref>
</sup>chronic kidney disease (CKD),<sup>
<xref rid="B12" ref-type="bibr">12</xref>
</sup>positive symptoms of androgenic deficiency (ADAM,
<italic toggle="yes">
<bold>Androgen Deficiency, in the Aging Male</bold>
</italic>
questionnaire),<sup>
<xref rid="B13" ref-type="bibr">13</xref>
</sup>and use of spironolactone.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study design</title><p>This was a cross-sectional study conducted in a referral hypertension center located in the Midwest of Brazil. Data were collected by the assistant staff during the outpatient visits.</p></sec><sec><title>Patients</title><p>Male patients aged from 18 to 85 years old, who attended at least one visit a year were included. Patients who did not perform the tests required, transsexual patients, and patients with cognitive impairment who were not able to answer the ADAM questionnaire were excluded.<sup>
<xref rid="B13" ref-type="bibr">13</xref>
</sup></p><p>Sample size calculation was carried out using the G*Power 3.1, with an expected prevalence of 12%,<sup>
<xref rid="B2" ref-type="bibr">2</xref>
</sup>confidence interval (CI) of 95%, level of significance 0.05 and 80% test power, resulting in a minimum of 148 individuals.</p></sec><sec><title>Data collection procedures</title><p>In this study, the following variables were considered for analysis: age, time of diagnosis of hypertension, number of antihypertensive classes, use of spironolactone, BMI,<sup>
<xref rid="B9" ref-type="bibr">9</xref>
</sup>presence of DM,<sup>
<xref rid="B10" ref-type="bibr">10</xref>
</sup>DLP,<sup>
<xref rid="B11" ref-type="bibr">11</xref>
</sup>CKD,<sup>
<xref rid="B12" ref-type="bibr">12</xref>
</sup>and positive symptoms of androgen deficiency (ADAM questionnaire<sup>
<xref rid="B13" ref-type="bibr">13</xref>
</sup>).</p><p>During the outpatient visits, after the patients signed the informed consent form, they had their weight and height measured, the abovementioned variables assessed, and laboratory tests, including total T (TT) measurements, were ordered. A TT cut-off of 300ng/dL (12nmol/L) was used to define TD, following the Endocrine Society<sup>
<xref rid="B1" ref-type="bibr">1</xref>
</sup>and the American Urological Association<sup>
<xref rid="B14" ref-type="bibr">14</xref>
</sup>recommendations. Blood samples were collected in fasting state in the morning and the TT levels were determined in randomized laboratories where the radioimmunoassay was available.<sup>
<xref rid="B15" ref-type="bibr">15</xref>
</sup></p><p>The ADAM questionnaire, from the Saint Louis University, consists of 10 "yes" or "no" questions about androgen deficiency symptoms.<sup>
<xref rid="B13" ref-type="bibr">13</xref>
</sup>This questionnaire has an 88% sensitivity and a 60% specificity,<sup>
<xref rid="B16" ref-type="bibr">16</xref>
</sup>and is recommended as a screening tool for hypogonadism.<sup>
<xref rid="B17" ref-type="bibr">17</xref>
</sup></p></sec><sec><title>Statistical analysis</title><p>A total of 239 participants were assessed and stratified into two groups according to TT status &#x02013; individuals with TD (
<italic toggle="yes">
<bold>n</bold>
</italic>
=64; 26.8%) and (2) eugonadal men (
<italic toggle="yes">
<bold>n</bold>
</italic>
=175; 73.2%). In descriptive statistics, categorical variables were described as absolute (n) and relative frequencies [
<italic toggle="yes">f(%)</italic>
]; and continuous variables were described as median and interquartile range (IQR). The categorical variables were TT status, age, time of hypertension, number of antihypertensive classes, BMI, DM DLP, CKD, use of spironolactone and ADAM questionnaire. Continuous quantitative variables were age, time of hypertension, number of antihypertensive classes, BMI and TT levels (ng/dL).</p><p>In the inferential statistics analysis, categorical variables were stratified by TT status and compared using the Fisher's exact test or the G's test. For statistically significant variables, the odds ratio (OR) and 95% CI were calculated to evaluate the odds of TD between the groups.</p><p>For continuous variables, data normality was calculated using the Kolmogorov&#x02013;Smirnov test, and variance homogeneity using the Levene's test. All continuous variables had a non-normal, non-homogeneous distribution (p&#x0003c;0.05) and, for this reason, the Mann-Whitney test for independent samples was used. Then, variables with a p&#x0003c;0.20 were analyzed using a multivariate linear regression model. Finally, the Spearman correlation was also used.<sup>
<xref rid="B18" ref-type="bibr">18</xref>
</sup></p></sec></sec><sec sec-type="results"><title>Results</title><p>A total of 276 hypertensive men were recruited; 37 were excluded &#x02013; 18 were older than 85 years, 11 declined to participate in the study, three had cognitive impairment, two had schizophrenia, two died before blood collection and one was transsexual. Among the 239 patients included, 175 (73.2%) had normal TT levels (eugonadism), yielding a TD prevalence of 26.8%. The results are summarized in the Central Illustration.</p><p>
<xref rid="t5" ref-type="table">Table 1</xref>
describes TT status (
<italic toggle="yes">
<bold>i.e</bold>
</italic>
., TD or eugonadal, age), time of hypertension diagnosis, number of antihypertensive classes, BMI,<sup>
<xref rid="B9" ref-type="bibr">9</xref>
</sup>DM,<sup>
<xref rid="B10" ref-type="bibr">10</xref>
</sup>DLP,<sup>
<xref rid="B11" ref-type="bibr">11</xref>
</sup>and CKD,<sup>
<xref rid="B12" ref-type="bibr">12</xref>
</sup>use of spironolactone and the ADAM questionnaire results.<sup>
<xref rid="B13" ref-type="bibr">13</xref>
</sup>These data are expressed as absolute (n) and relative frequencies [
<italic toggle="yes">f(%)</italic>
].</p><table-wrap position="float" id="t5"><label>Table 1</label><caption><title>Descriptive statistics of categorical variables, expressed as absolute (n) and relative frequencies [
<italic toggle="yes">f(%)</italic>
], of 239 patients, Goiania, Brazil, 2023</title></caption><table frame="hsides" rules="groups"><colgroup width="32%" span="1"><col width="1%" span="1"/><col width="1%" span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000"><tr style="background-color:#76B4CF"><th valign="middle" align="left" colspan="3" rowspan="1">Variables (N=239)</th><th valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</th><th valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">f(%)</italic>
</th></tr></thead><tbody style="border-bottom: thin solid; border-color: #000000"><tr><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Testosterone status</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Testosterone deficiency</td><td valign="middle" align="left" rowspan="1" colspan="1">64</td><td valign="middle" align="left" rowspan="1" colspan="1">26.8</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Eugonadal</td><td valign="middle" align="left" rowspan="1" colspan="1">175</td><td valign="middle" align="left" rowspan="1" colspan="1">73.2</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Age (years)</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">&#x0003c; 60 years</td><td valign="middle" align="left" rowspan="1" colspan="1">91</td><td valign="middle" align="left" rowspan="1" colspan="1">38.1</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">&#x02265; 60 years</td><td valign="middle" align="left" rowspan="1" colspan="1">148</td><td valign="middle" align="left" rowspan="1" colspan="1">61.9</td></tr><tr><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Time of hypertension (years)</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">&#x0003c; 15 years</td><td valign="middle" align="left" rowspan="1" colspan="1">126</td><td valign="middle" align="left" rowspan="1" colspan="1">52.7</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">&#x02265; 15 years</td><td valign="middle" align="left" rowspan="1" colspan="1">97</td><td valign="middle" align="left" rowspan="1" colspan="1">40.6</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Not informed</td><td valign="middle" align="left" rowspan="1" colspan="1">16</td><td valign="middle" align="left" rowspan="1" colspan="1">6.7</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Number of antihypertensive classes</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">None</td><td valign="middle" align="left" rowspan="1" colspan="1">8</td><td valign="middle" align="left" rowspan="1" colspan="1">3.3</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">&#x0003c;3</td><td valign="middle" align="left" rowspan="1" colspan="1">184</td><td valign="middle" align="left" rowspan="1" colspan="1">77.0</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">&#x0003e;3</td><td valign="middle" align="left" rowspan="1" colspan="1">47</td><td valign="middle" align="left" rowspan="1" colspan="1">19.7</td></tr><tr><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>BMI (Kg/m<sup>2</sup>)</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Normal (18.6 - 24.9)</td><td valign="middle" align="left" rowspan="1" colspan="1">51</td><td valign="middle" align="left" rowspan="1" colspan="1">21.3</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Overweight (25.0 - 29.9)</td><td valign="middle" align="left" rowspan="1" colspan="1">100</td><td valign="middle" align="left" rowspan="1" colspan="1">41.8</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Obesity (&#x02265;30.0)</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1">Grade I (30.0 - 34.9)</td><td valign="middle" align="left" rowspan="1" colspan="1">58</td><td valign="middle" align="left" rowspan="1" colspan="1">24.3</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1">Grade II (35.0 - 39.0)</td><td valign="middle" align="left" rowspan="1" colspan="1">20</td><td valign="middle" align="left" rowspan="1" colspan="1">8.4</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1">Grade III (&#x02265;40.0)</td><td valign="middle" align="left" rowspan="1" colspan="1">8</td><td valign="middle" align="left" rowspan="1" colspan="1">3.3</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Not informed</td><td valign="middle" align="left" rowspan="1" colspan="1">2</td><td valign="middle" align="left" rowspan="1" colspan="1">0.8</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Diabetes</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Yes</td><td valign="middle" align="left" rowspan="1" colspan="1">78</td><td valign="middle" align="left" rowspan="1" colspan="1">32.6</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">No</td><td valign="middle" align="left" rowspan="1" colspan="1">161</td><td valign="middle" align="left" rowspan="1" colspan="1">67.4</td></tr><tr><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Dyslipidemia</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Yes</td><td valign="middle" align="left" rowspan="1" colspan="1">172</td><td valign="middle" align="left" rowspan="1" colspan="1">72.0</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">No</td><td valign="middle" align="left" rowspan="1" colspan="1">67</td><td valign="middle" align="left" rowspan="1" colspan="1">28.0</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Chronic kidney disease</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Yes</td><td valign="middle" align="left" rowspan="1" colspan="1">78</td><td valign="middle" align="left" rowspan="1" colspan="1">32.6</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">No</td><td valign="middle" align="left" rowspan="1" colspan="1">161</td><td valign="middle" align="left" rowspan="1" colspan="1">67.4</td></tr><tr><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Spironolactone</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Yes</td><td valign="middle" align="left" rowspan="1" colspan="1">23</td><td valign="middle" align="left" rowspan="1" colspan="1">9.6</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">No</td><td valign="middle" align="left" rowspan="1" colspan="1">216</td><td valign="middle" align="left" rowspan="1" colspan="1">90.4</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>ADAM questionnaire</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Negative</td><td valign="middle" align="left" rowspan="1" colspan="1">24</td><td valign="middle" align="left" rowspan="1" colspan="1">10.0</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Positive</td><td valign="middle" align="left" rowspan="1" colspan="1">184</td><td valign="middle" align="left" rowspan="1" colspan="1">77.0</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Not informed</td><td valign="middle" align="left" rowspan="1" colspan="1">31</td><td valign="middle" align="left" rowspan="1" colspan="1">13.0</td></tr></tbody></table><table-wrap-foot><fn id="TFN6"><p>N: total number of individuals in the sample; n: absolute frequency; f(%): relative frequency; BMI: body mass index; ADAM: Androgen Deficiency, in the Aging Male.</p></fn></table-wrap-foot></table-wrap><p>
<xref rid="t6" ref-type="table">Table 2</xref>
compares the variables and respective categories between TD and eugonadal patients. There was a statistically significant difference in BMI (p=0.0007) between the groups, with a greater number of obese patients in the TD group.</p><table-wrap position="float" id="t6"><label>Table 2</label><caption><title>Inferential statistics of categorical variables of 239 participants, stratified by testosterone status; Goiania, Brazil, 2023</title></caption><table frame="hsides" rules="groups"><colgroup width="16%" span="1"><col width="1%" span="1"/><col width="1%" span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000"><tr style="background-color:#76B4CF"><th valign="middle" align="left" colspan="3" rowspan="2">Variables (N=239)</th><th valign="middle" align="center" colspan="2" style="border-bottom: thin solid; border-color: #000000" rowspan="1">Testosterone deficiency (n=64; 26.8%)</th><th valign="middle" align="center" colspan="2" style="border-bottom: thin solid; border-color: #000000" rowspan="1">Eugonadal (n=175; 73,2%)</th><th valign="middle" align="center" rowspan="2" colspan="1">p-value
<xref rid="TFN8" ref-type="table-fn">*</xref></th></tr><tr style="background-color:#76B4CF"><th valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</th><th valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">f(%)</italic>
</th><th valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</th><th valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">f(%)</italic>
</th></tr></thead><tbody style="border-bottom: thin solid; border-color: #000000"><tr><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Age (years)</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">&#x0003c; 60 years</td><td valign="middle" align="left" rowspan="1" colspan="1">18</td><td valign="middle" align="left" rowspan="1" colspan="1">28.1</td><td valign="middle" align="left" rowspan="1" colspan="1">73</td><td valign="middle" align="left" rowspan="1" colspan="1">41.7</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">&#x02265; 60 years</td><td valign="middle" align="left" rowspan="1" colspan="1">46</td><td valign="middle" align="left" rowspan="1" colspan="1">71.9</td><td valign="middle" align="left" rowspan="1" colspan="1">102</td><td valign="middle" align="left" rowspan="1" colspan="1">58.3</td><td valign="middle" align="left" rowspan="1" colspan="1">0.0520</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Time of hypertension (years)</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">&#x0003c; 15 years</td><td valign="middle" align="left" rowspan="1" colspan="1">28</td><td valign="middle" align="left" rowspan="1" colspan="1">43.8</td><td valign="middle" align="left" rowspan="1" colspan="1">98</td><td valign="middle" align="left" rowspan="1" colspan="1">56.0</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">&#x02265; 15 years</td><td valign="middle" align="left" rowspan="1" colspan="1">30</td><td valign="middle" align="left" rowspan="1" colspan="1">46.9</td><td valign="middle" align="left" rowspan="1" colspan="1">67</td><td valign="middle" align="left" rowspan="1" colspan="1">38.3</td><td valign="middle" align="left" rowspan="1" colspan="1">0.1418</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Not informed</td><td valign="middle" align="left" rowspan="1" colspan="1">6</td><td valign="middle" align="left" rowspan="1" colspan="1">9.4</td><td valign="middle" align="left" rowspan="1" colspan="1">10</td><td valign="middle" align="left" rowspan="1" colspan="1">5.7</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" colspan="2" rowspan="1">
<bold>Number of antihypertensive classes</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">None</td><td valign="middle" align="left" rowspan="1" colspan="1">0</td><td valign="middle" align="left" rowspan="1" colspan="1">0.0</td><td valign="middle" align="left" rowspan="1" colspan="1">8</td><td valign="middle" align="left" rowspan="1" colspan="1">4.6</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">&#x0003c; 3</td><td valign="middle" align="left" rowspan="1" colspan="1">52</td><td valign="middle" align="left" rowspan="1" colspan="1">81.3</td><td valign="middle" align="left" rowspan="1" colspan="1">132</td><td valign="middle" align="left" rowspan="1" colspan="1">75.4</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">&#x0003e;3</td><td valign="middle" align="left" rowspan="1" colspan="1">12</td><td valign="middle" align="left" rowspan="1" colspan="1">18.8</td><td valign="middle" align="left" rowspan="1" colspan="1">35</td><td valign="middle" align="left" rowspan="1" colspan="1">20.0</td><td valign="middle" align="left" rowspan="1" colspan="1">0.0732</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>BMI (Kg/m<sup>2</sup>)</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Normal (18.6 - 24.9)</td><td valign="middle" align="left" rowspan="1" colspan="1">5</td><td valign="middle" align="left" rowspan="1" colspan="1">7.8</td><td valign="middle" align="left" rowspan="1" colspan="1">46</td><td valign="middle" align="left" rowspan="1" colspan="1">26.3</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Overweight (25.0 - 29.9)</td><td valign="middle" align="left" rowspan="1" colspan="1">23</td><td valign="middle" align="left" rowspan="1" colspan="1">35.9</td><td valign="middle" align="left" rowspan="1" colspan="1">77</td><td valign="middle" align="left" rowspan="1" colspan="1">44.0</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Obesity (&#x02265;30.0)</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1">Grade I (30.0 - 34.9)</td><td valign="middle" align="left" rowspan="1" colspan="1">24</td><td valign="middle" align="left" rowspan="1" colspan="1">37.5</td><td valign="middle" align="left" rowspan="1" colspan="1">34</td><td valign="middle" align="left" rowspan="1" colspan="1">19.4</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1">Grade II (35.0 - 39.0)</td><td valign="middle" align="left" rowspan="1" colspan="1">9</td><td valign="middle" align="left" rowspan="1" colspan="1">14.1</td><td valign="middle" align="left" rowspan="1" colspan="1">11</td><td valign="middle" align="left" rowspan="1" colspan="1">6.3</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1">Grade III (&#x02265;40.0)</td><td valign="middle" align="left" rowspan="1" colspan="1">3</td><td valign="middle" align="left" rowspan="1" colspan="1">4.7</td><td valign="middle" align="left" rowspan="1" colspan="1">5</td><td valign="middle" align="left" rowspan="1" colspan="1">2.9</td><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>0.0007</bold>
</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Not informed</td><td valign="middle" align="left" rowspan="1" colspan="1">0</td><td valign="middle" align="left" rowspan="1" colspan="1">0.0</td><td valign="middle" align="left" rowspan="1" colspan="1">2</td><td valign="middle" align="left" rowspan="1" colspan="1">1.1</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Diabetes</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Yes</td><td valign="middle" align="left" rowspan="1" colspan="1">26</td><td valign="middle" align="left" rowspan="1" colspan="1">40.6</td><td valign="middle" align="left" rowspan="1" colspan="1">52</td><td valign="middle" align="left" rowspan="1" colspan="1">29.7</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">No</td><td valign="middle" align="left" rowspan="1" colspan="1">38</td><td valign="middle" align="left" rowspan="1" colspan="1">59.4</td><td valign="middle" align="left" rowspan="1" colspan="1">123</td><td valign="middle" align="left" rowspan="1" colspan="1">70.3</td><td valign="middle" align="left" rowspan="1" colspan="1">0.1112</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Dyslipidemia</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Yes</td><td valign="middle" align="left" rowspan="1" colspan="1">49</td><td valign="middle" align="left" rowspan="1" colspan="1">76.6</td><td valign="middle" align="left" rowspan="1" colspan="1">123</td><td valign="middle" align="left" rowspan="1" colspan="1">70.3</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">No</td><td valign="middle" align="left" rowspan="1" colspan="1">15</td><td valign="middle" align="left" rowspan="1" colspan="1">23.4</td><td valign="middle" align="left" rowspan="1" colspan="1">52</td><td valign="middle" align="left" rowspan="1" colspan="1">29.7</td><td valign="middle" align="left" rowspan="1" colspan="1">0.3388</td></tr><tr><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Chronic kidney disease</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Yes</td><td valign="middle" align="left" rowspan="1" colspan="1">24</td><td valign="middle" align="left" rowspan="1" colspan="1">37.5</td><td valign="middle" align="left" rowspan="1" colspan="1">54</td><td valign="middle" align="left" rowspan="1" colspan="1">30.9</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">No</td><td valign="middle" align="left" rowspan="1" colspan="1">40</td><td valign="middle" align="left" rowspan="1" colspan="1">62.5</td><td valign="middle" align="left" rowspan="1" colspan="1">121</td><td valign="middle" align="left" rowspan="1" colspan="1">69.1</td><td valign="middle" align="left" rowspan="1" colspan="1">0.3321</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>Spironolactone</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Yes</td><td valign="middle" align="left" rowspan="1" colspan="1">8</td><td valign="middle" align="left" rowspan="1" colspan="1">12.5</td><td valign="middle" align="left" rowspan="1" colspan="1">15</td><td valign="middle" align="left" rowspan="1" colspan="1">8.6</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">No</td><td valign="middle" align="left" rowspan="1" colspan="1">56</td><td valign="middle" align="left" rowspan="1" colspan="1">87.5</td><td valign="middle" align="left" rowspan="1" colspan="1">161</td><td valign="middle" align="left" rowspan="1" colspan="1">92.0</td><td valign="middle" align="left" rowspan="1" colspan="1">0.3546</td></tr><tr><td valign="middle" align="left" colspan="3" rowspan="1">
<bold>ADAM questionnaire</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Negative</td><td valign="middle" align="left" rowspan="1" colspan="1">4</td><td valign="middle" align="left" rowspan="1" colspan="1">6.3</td><td valign="middle" align="left" rowspan="1" colspan="1">20</td><td valign="middle" align="left" rowspan="1" colspan="1">11.4</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Positive</td><td valign="middle" align="left" rowspan="1" colspan="1">51</td><td valign="middle" align="left" rowspan="1" colspan="1">79.7</td><td valign="middle" align="left" rowspan="1" colspan="1">133</td><td valign="middle" align="left" rowspan="1" colspan="1">76.0</td><td valign="middle" align="left" rowspan="1" colspan="1">0.2483</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" colspan="2" rowspan="1">Not informed</td><td valign="middle" align="left" rowspan="1" colspan="1">9</td><td valign="middle" align="left" rowspan="1" colspan="1">14.1</td><td valign="middle" align="left" rowspan="1" colspan="1">22</td><td valign="middle" align="left" rowspan="1" colspan="1">12.6</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TFN7"><p>N: total number of individuals in the sample; n: absolute frequency; f(%): relative frequency; BMI: body mass index; ADAM: Androgen Deficiency, in the Aging Male;</p></fn><fn id="TFN8"><label>*</label><p>chi-square test, Fisher's exact test or the G test.</p></fn></table-wrap-foot></table-wrap><p>There was a predominance of obese individuals in the TD group, BMI (
<italic toggle="yes">&#x003c7;</italic>
<sup>2</sup>=18,10; p=0.0001). For comparison between BMI categories, there were statistically significant differences between: normal BMI vs. obese (OR=6.62; 95%CI=2.39&#x02013;18.32; p=0.0002), with increment of relative risk of 32.1; overweight vs. obese (OR=2.41; 95%CI=1.28&#x02013;4.54; p=0.0094), with increment of relative risk of 18.9%.
<xref rid="t7" ref-type="table">Table 3</xref>
shows statistically significant differences between the TD and eugonadal groups in the time of hypertension (p=0.317), BMI (p&#x0003c;0.0001) and TT (p&#x0003c;0.0001).</p><table-wrap position="float" id="t7"><label>Table 3</label><caption><title>Median and interquartile range (IQR) of continuous quantitative variables of 239 patients, stratified and compared by testosterone status; Goiania, Brazil, 2023</title></caption><table frame="hsides" rules="groups"><colgroup width="9%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000"><tr style="background-color:#76B4CF"><th valign="middle" align="left" rowspan="3" colspan="1">Variables</th><th valign="middle" align="center" colspan="3" style="border-bottom: thin solid; border-color: #000000" rowspan="1">DT (n=64; 26.8%)</th><th valign="middle" align="center" colspan="3" style="border-left: thin solid; border-bottom: thin solid; border-color: #000000" rowspan="1">Eugonadal (n=175; 73.2%)</th><th valign="middle" align="center" rowspan="3" style="border-left: thin solid; border-right: thin solid; border-color: #000000" colspan="1">p-valor
<xref rid="TFN10" ref-type="table-fn">*</xref></th><th valign="middle" align="center" colspan="3" style="border-bottom: thin solid; border-color: #000000" rowspan="1">Total (N=239)</th></tr><tr style="background-color:#76B4CF"><th valign="middle" align="center" rowspan="2" colspan="1">
<italic toggle="yes">Mediana</italic>
</th><th valign="middle" align="center" colspan="2" style="border-bottom: thin solid; border-color: #000000" rowspan="1">
<italic toggle="yes">IQR</italic>
</th><th valign="middle" align="center" rowspan="2" style="border-left: thin solid; border-color: #000000" colspan="1">
<italic toggle="yes">Mediana</italic>
</th><th valign="middle" align="center" colspan="2" style="border-bottom: thin solid; border-color: #000000" rowspan="1">
<italic toggle="yes">IQR</italic>
</th><th valign="middle" align="center" rowspan="3" style="border-left: thin solid; border-color: #000000" colspan="1">
<italic toggle="yes">Mediana</italic>
</th><th valign="middle" align="center" colspan="2" style="border-bottom: thin solid; border-color: #000000" rowspan="1">
<italic toggle="yes">IQR</italic>
</th></tr><tr style="background-color:#76B4CF"><th valign="middle" align="center" rowspan="1" colspan="1">25%</th><th valign="middle" align="center" rowspan="1" colspan="1">75%</th><th valign="middle" align="center" rowspan="1" colspan="1">25%</th><th valign="middle" align="center" rowspan="1" colspan="1">75%</th><th valign="middle" align="center" rowspan="1" colspan="1">25%</th><th valign="middle" align="center" rowspan="1" colspan="1">75%</th></tr></thead><tbody style="border-bottom: thin solid; border-color: #000000"><tr><td valign="middle" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="middle" align="center" rowspan="1" colspan="1">63.5</td><td valign="middle" align="center" rowspan="1" colspan="1">58.8</td><td valign="middle" align="center" rowspan="1" colspan="1">70.0</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">62.0</td><td valign="middle" align="center" rowspan="1" colspan="1">55.0</td><td valign="middle" align="center" rowspan="1" colspan="1">70.5</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">0.3476</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">63.0</td><td valign="middle" align="center" rowspan="1" colspan="1">55.5</td><td valign="middle" align="center" rowspan="1" colspan="1">70.0</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1">Time of hypertension (years)</td><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>16.5</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">8.0</td><td valign="middle" align="center" rowspan="1" colspan="1">24.3</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">
<bold>14.0</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">6.0</td><td valign="middle" align="center" rowspan="1" colspan="1">20.0</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">
<bold>0.0317</bold>
</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">15.0</td><td valign="middle" align="center" rowspan="1" colspan="1">7.0</td><td valign="middle" align="center" rowspan="1" colspan="1">20.0</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Number of antihypertensives</td><td valign="middle" align="center" rowspan="1" colspan="1">3.0</td><td valign="middle" align="center" rowspan="1" colspan="1">2.0</td><td valign="middle" align="center" rowspan="1" colspan="1">3.0</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">3.0</td><td valign="middle" align="center" rowspan="1" colspan="1">2.0</td><td valign="middle" align="center" rowspan="1" colspan="1">3.0</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">0.7242</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">3.0</td><td valign="middle" align="center" rowspan="1" colspan="1">2.0</td><td valign="middle" align="center" rowspan="1" colspan="1">3.0</td></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1">BMI (Kg/m<sup>2</sup>)</td><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>31.0</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">27.3</td><td valign="middle" align="center" rowspan="1" colspan="1">34.5</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">
<bold>27.7</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">24.9</td><td valign="middle" align="center" rowspan="1" colspan="1">30.8</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">28.5</td><td valign="middle" align="center" rowspan="1" colspan="1">25.4</td><td valign="middle" align="center" rowspan="1" colspan="1">31.6</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Total testosterone (ng/dL)</td><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>220.0</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">182.5</td><td valign="middle" align="center" rowspan="1" colspan="1">262.8</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">
<bold>449.0</bold>
</td><td valign="middle" align="center" rowspan="1" colspan="1">360.0</td><td valign="middle" align="center" rowspan="1" colspan="1">532.0</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td><td valign="middle" align="center" style="border-left: thin solid; border-color: #000000" rowspan="1" colspan="1">376.7</td><td valign="middle" align="center" rowspan="1" colspan="1">286.3</td><td valign="middle" align="center" rowspan="1" colspan="1">491.5</td></tr></tbody></table><table-wrap-foot><fn id="TFN9"><p>TD: Testosterone deficiency; N: total number of individuals in the sample; Median: measure of central tendency; IQR: interquartile range (25% - 75%); BMI: body mass index.</p></fn><fn id="TFN10"><label>*</label><p>Mann-Whitney test for independent samples</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t8"><label>Table 4</label><caption><title>Spearman correlation between continuous quantitative variables; Goiania, Brazil, 2023</title></caption><table frame="hsides" rules="groups"><colgroup width="14%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000"><tr style="background-color:#76B4CF"><th valign="middle" align="left" colspan="2" rowspan="1">Variables</th><th valign="middle" align="center" rowspan="1" colspan="1">Testosterone (ng/dL)</th><th valign="middle" align="center" rowspan="1" colspan="1">Age (years)</th><th valign="middle" align="center" rowspan="1" colspan="1">SAH (years)</th><th valign="middle" align="center" rowspan="1" colspan="1">Antihypertensives</th><th valign="middle" align="center" rowspan="1" colspan="1">BMI (Kg/m<sup>2</sup>)</th></tr></thead><tbody style="border-bottom: thin solid; border-color: #000000"><tr><td valign="middle" align="left" rowspan="2" colspan="1">Testosterone</td><td valign="middle" align="left" rowspan="1" colspan="1">&#x003c1; (rho)</td><td valign="middle" align="left" rowspan="1" colspan="1">1.0000</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">
<italic toggle="yes">p-valor</italic>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="2" colspan="1">Age (years)</td><td valign="middle" align="left" rowspan="1" colspan="1">&#x003c1; (rho)</td><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>-0.1760</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">1.0000</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1">
<italic toggle="yes">p-valor</italic>
</td><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>0.0068</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="2" colspan="1">SAH (years)</td><td valign="middle" align="left" rowspan="1" colspan="1">&#x003c1; (rho)</td><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>-0.1410</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>0.3530</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">1.0000</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">
<italic toggle="yes">p-valor</italic>
</td><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>0.0366</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="2" colspan="1">Antihypertensives</td><td valign="middle" align="left" rowspan="1" colspan="1">&#x003c1; (rho)</td><td valign="middle" align="left" rowspan="1" colspan="1">-0.1046</td><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>0.1700</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>0.2640</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">1.0000</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:#C7DFEC"><td valign="middle" align="left" rowspan="1" colspan="1">
<italic toggle="yes">p-valor</italic>
</td><td valign="middle" align="left" rowspan="1" colspan="1">0.1083</td><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>0.0083</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>0.0001</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="2" colspan="1">BMI (kg/m<sup>2</sup>)</td><td valign="middle" align="left" rowspan="1" colspan="1">&#x003c1; (rho)</td><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>-0.2600</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>-0.2330</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">-0.0048</td><td valign="middle" align="left" rowspan="1" colspan="1">0.0521</td><td valign="middle" align="left" rowspan="1" colspan="1">1.0000</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">
<italic toggle="yes">p-valor</italic>
</td><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>0.0001</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>0.0003</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">0.9434</td><td valign="middle" align="left" rowspan="1" colspan="1">0.4248</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TFN11"><p>SAH: systemic arterial hypertension; BMI: body mass index.</p></fn></table-wrap-foot></table-wrap><p>The Spearman correlation between continuous quantitative variables revealed a low, inversely proportional and statistically significant relationship between TT and BMI (&#x003c1;=-0.26; p=0.0001), age (&#x003c1;=-0.1760; p=0.0069) and time of hypertension diagnosis (&#x003c1;=-0.1410; p=0.0366).</p><p>The variables that showed statistically significant difference are shown in
<xref rid="f4" ref-type="fig">Figure 1</xref>
: (a) TT; (b) BMI and (c) time of diagnosis of HA. Patients with TD showed median TT of 222.0 ng/dL, BMI of 31.0 Kg/m<sup>2</sup>and 16.5 years of diagnosis of HA, whereas the eugonadal subjects showed median TT of 449.0 ng/dL, BMI of 27.7 Kg/m<sup>2</sup>and 14.0 years of diagnosis of HA.</p><fig position="float" id="f4"><label>Figure 1</label><caption><title>Box plots with median, interquartile range (25% and 75%), minimum and maximum values of variables that showed statistically significant difference: (a) total testosterone; (b) Body mass index and (c) time of diagnosis of hypertension; Goiania, Brazil.</title></caption><graphic xlink:href="0066-782X-abc-121-03-e20230138-gf01-en" position="float"/></fig><p>A multivariate linear regression analysis of variables with low p-values (p&#x0003c;0.20) was performed, since all statistical assumptions (linearity, independency, homoscedasticity, normality of residuals, non-collinearity and lack of outliers) were met. The variables that had the strongest influence on TT were BMI and age. A one-year increase in age was associated with a 3.79ng/dL decrease in TT (B=-3.79; 95%CI=-5.57 to -2.06; p&#x0003c;0.0001), and a one unit increase in BMI was associated with a 8.44 ng/dL decrease in TT (B=-8.44; 95%CI= -12.57 to -4.32; p&#x0003c;0.0001) (
<xref rid="f5" ref-type="fig">Figure 2</xref>
).</p><fig position="float" id="f5"><label>Figure 2</label><caption><title>Relationship between total testosterone (ng/dL) and body mass index (BMI, Kg/m<sup>2</sup>) of all participants (N=239).</title></caption><graphic xlink:href="0066-782X-abc-121-03-e20230138-gf02-en" position="float"/></fig></sec><sec sec-type="discussion"><title>Discussion</title><p>To our knowledge, this is the first study to evaluate the prevalence of TD in a hypertensive population. We found a 25.8% prevalence of TD, and an association between TD and BMI (p=0.0007).</p><p>Obesity is the clinical condition with the strongest relationship with decreased TT levels in men.<sup>
<xref rid="B19" ref-type="bibr">19</xref>
,
<xref rid="B20" ref-type="bibr">20</xref>
</sup>Weight excess causes HPT axis suppression in a functional and potentially reversible manner.<sup>
<xref rid="B19" ref-type="bibr">19</xref>
</sup>Low T levels lead to an increase in adiposity due to the lack of inhibition of adipogenesis and lipid uptake, mediated by the lipoprotein lipase enzyme, mainly in abdominal fat deposits.<sup>
<xref rid="B21" ref-type="bibr">21</xref>
</sup>On the other hand, weight loss can lead to amelioration of gonadal function; therefore, the relationship between weight excess and T levels is bidirectional, establishing a vicious cycle.<sup>
<xref rid="B21" ref-type="bibr">21</xref>
</sup>In the present study, analysis of the BMI categories showed that the increase in BMI from normal weight to obesity led to an increase in relative risk of 18.9%. Besides, a one Kg/m<sup>2</sup>increase in BMI was associated with an 8.44 ng/dL decrease in TT (B=-8.44; 95%CI= -12.57 to -4.32; p&#x0003c;0.0001).</p><p>There is a natural decline of approximately 1% a year in male sexual hormones with aging between 40 and 70 years of age.<sup>
<xref rid="B22" ref-type="bibr">22</xref>
</sup>The prevalence of late onset hypogonadism is not only associated with aging but also with the increase in BMI and coexisting diseases.<sup>
<xref rid="B22" ref-type="bibr">22</xref>
</sup>In this regard, our study aimed to correlate the advance in age with the decrease in TT levels. However, despite marginal, the p-value was not statistically significant (p=0.0520). Age, in turn, has shown to be a significant variable in the multivariate analysis, and a one-year increase in age was associated with a 3.79ng/dL decrease in TT (
<italic toggle="yes">B</italic>
=-3.79; 95%CI=-5.57 to -2.06; p&#x0003c;0.0001). Probably, these findings would be more expressive in a larger sample.</p><p>Svartberg et al.<sup>
<xref rid="B7" ref-type="bibr">7</xref>
</sup>assessed blood pressure in 1,578 men, and TT values were inversely related to systolic blood pressure (p&#x0003c;0.001) and left ventricular mass (p&#x0003c;0.001). However, after adjustments for BMI, the results suggested that this relationship was mediated by obesity.<sup>
<xref rid="B7" ref-type="bibr">7</xref>
</sup>Similar results were found by Zitzmann &#x00026; Nieschlag,<sup>
<xref rid="B23" ref-type="bibr">23</xref>
</sup>and T reposition resulted in significant decrements of these parameters and heart rate. Based on this rational, the present study evaluated associations of TT values with the time of hypertension diagnosis (p=0.1418) and the number of antihypertensive classes used by the patients (p=0.0732). However, the findings were not statistically significant, which may be justified by the fact that the factors investigated, although published for the first time and indirectly related to blood pressure measurements, ultimately differ from them.</p><p>Spironolactone is an antihypertensive agent that has antiandrogenic properties due to multiple mechanisms.<sup>
<xref rid="B24" ref-type="bibr">24</xref>
</sup>Thus, we investigated whether its use in the treatment of hypertension would be a confound factor for its association with TT values, which was not confirmed in our sample (p=0.3546).</p><p>Clinical presentation of TD may be easily neglected, since the symptoms are common to those of aging and other comorbidities.<sup>
<xref rid="B22" ref-type="bibr">22</xref>
</sup>The Saint Louis University ADAM questionnaire<sup>
<xref rid="B13" ref-type="bibr">13</xref>
</sup>has been widely used as a screening tool for men at risk of androgen deficiency.<sup>
<xref rid="B16" ref-type="bibr">16</xref>
</sup>In the present study, we did not observe any correlation between TT levels and positive ADAM questionnaire. In our sample, there was only 10% of patients with a negative questionnaire, which may be explained by the fact that hypertension
<italic toggle="yes">per se</italic>
is associated with the complaints assessed by the questionnaire, hence affecting the specificity of the instrument.</p><p>Testicular dysfunction affects nearly 50% of men with CKD,<sup>
<xref rid="B12" ref-type="bibr">12</xref>
</sup>in different stages,<sup>
<xref rid="B24" ref-type="bibr">24</xref>
</sup>and is associated with an increase in all-cause mortality in this population.<sup>
<xref rid="B25" ref-type="bibr">25</xref>
</sup>Therefore, we investigated whether CKD was associated with TD, which was not confirmed in this study (
<italic toggle="yes">p</italic>
=0.3321). This could be explained by the fact that most (93.5%) of our patients with CKD had a glomerular filtration rate greater than 30 mL/min/1.72m<sup>2</sup>.</p><p>In addition, serum T levels are also associated with lipid metabolism, with an inverse relationship between T values and triglycerides, total cholesterol and LDL cholesterol, whereas good T levels are associated with normal HDL levels.<sup>
<xref rid="B26" ref-type="bibr">26</xref>
</sup>Schiffer et al.<sup>
<xref rid="B27" ref-type="bibr">27</xref>
</sup>observed that patients receiving androgen deprivation therapy developed DLP. In the present study, we did not observe a statistically significant correlation between the presence of DLP and TD (p=0.3388), which may be explained by the fact that our sample consisted of intensely treated patients.</p><p>Nearly one third of patients with type 2 DM (DM2) has low T levels.<sup>
<xref rid="B28" ref-type="bibr">28</xref>
</sup>Oh et al.<sup>
<xref rid="B29" ref-type="bibr">29</xref>
</sup>suggested that TD is a potential risk factor for DM2. Men with high T levels have a 42% lower risk of DM2, indicating that high levels of the hormone are protective against the disease.<sup>
<xref rid="B30" ref-type="bibr">30</xref>
</sup>However, in our study, the presence of DM did not show a significant correlation with TD (p=0.112). This may be due to the heterogeneity of our study population, with different glycemic control and treatment intensity; 19.5% of the DM patients were prediabetic,<sup>
<xref rid="B10" ref-type="bibr">10</xref>
</sup>and few patients were on insulin therapy.</p><p>T is the main male sexual hormone,<sup>
<xref rid="B22" ref-type="bibr">22</xref>
</sup>and it plays a crucial role in reproductive function, as well as in individuals&#x02019; general health and quality of life.<sup>
<xref rid="B15" ref-type="bibr">15</xref>
</sup>Current evidence strongly supports the premise that low T levels is an important biomarker of morbidity and mortality in men,<sup>
<xref rid="B31" ref-type="bibr">31</xref>
</sup>with patients with lower T levels experiencing more severe metabolic consequences.<sup>
<xref rid="B21" ref-type="bibr">21</xref>
</sup></p><p>After T is produced, it circulates bound to either sex hormone binding globulin (SHBG) or albumin, and only a small fraction circulates as free testosterone,<sup>
<xref rid="B15" ref-type="bibr">15</xref>
</sup>which is its active form. Concentrations of SHBG vary with age, and presence of chronic diseases such as obesity.<sup>
<xref rid="B32" ref-type="bibr">32</xref>
</sup></p><p>This was a real-world study; one of its limitations is the fact that laboratory tests were performed randomly, mostly in the public sector and, for this reason, the biochemical methods were not uniform. Besides, free testosterone levels were not assessed due to high costs of the tests that would enable its indirect estimation.<sup>
<xref rid="B15" ref-type="bibr">15</xref>
</sup></p><p>As far as we know, this is the first study to determine the prevalence of TD in a hypertensive population. Potential deleterious effects of androgen deficiency are possibly intensified in this context of increased cardiovascular risk, which draws attention to the importance of the identification of this condition. The growing prevalence of obesity today reinforces the need for strategies that promote its control, especially in hypertensive men, since its repercussions may impact different aspects of their lives, including sexual life, fertility, and quality of life.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>The present study found a high prevalence of TD (26.8%) in hypertensive patients, but no association of TT levels with the time of diagnosis of hypertension, number of antihypertensive classes, use of spironolactone, positive symptoms of TD, presence of DM, DLP, or CKD was found. On the other hand, there was a strong, inverse relationship between TT and BMI, and one unit increase in BMI was associated with an 8.44 ng/dL decrease in TT. Also, an increment of one year old was associated with a decrease of 3.79 ng/dL in TT concentrations. Further studies are needed to elucidate the possible association between hypertension and TD.</p></sec></body><back><ack><title>Acknowledgements</title><p>We thank Beatriz dos Santos and Cl&#x000e1;udia Zorzetti, secretaries of the
<italic toggle="yes">Liga de Hipertens&#x000e3;o Arterial</italic>
for their collaboration in this study.</p></ack><fn-group><fn fn-type="financial-disclosure" id="fn5"><p>
<bold>Sources of funding</bold>
</p><p>There were no external funding sources for this study.</p></fn><fn fn-type="other" id="fn6"><p>
<bold>Study association</bold>
</p><p>This article is part of the thesis of doctoral submitted by Hospital das Cl&#x000ed;nicas da Universidade Federal de Goi&#x000e1;s &#x02013; CEP/HC/UFG, from Universidade Federal de Goi&#x000e1;s.</p></fn><fn fn-type="other" id="fn7"><p>
<bold>Ethics approval and consent to participate</bold>
</p><p>This study was approved by the Ethics Committee of the Hospital das Cl&#x000ed;nicas da Universidade Federal de Goi&#x000e1;s &#x02013; CEP/HC/UFG under the protocol number 2.552.801. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study.</p></fn><fn fn-type="other" id="fn8"><p>Editor responsible for the review: Gl&#x000e1;ucia Maria Moraes de Oliveira</p></fn></fn-group></back></sub-article></article>